

Curriculum Vitae
Siu Fun Wong, PharmD, FASHP, FCSHP

Business Address

Chapman University
Harry and Diane Rinker Health Science Campus
9401 Jeronimo Road
Irvine, California 92618
Tel: (714)516-5858
e-mail: sfwong@chapman.edu

Current Title and Department

8/2013 - Present	Associate Dean of Assessment and Scholarship Professor, Oncology (Tenured) – Founding Faculty Chapman University School of Pharmacy Orange, California
8/2008 - Present	Leader of Pharmaceutical Sciences SWOG Chair Office, Oregon Health & Sciences University, OR (6/2013 – present) SWOG Chair Office, University of Michigan, IL (8/2008 – 5/2013)
6/2003- Present	Expert Examiner North American Pharmacist Licensure Examination Review Committee (NRC) National Association of Boards of Pharmacy (NABP), Chicago, IL

Academic Positions

7/2010- 3/2013	Professor, Oncology Department of Pharmacotherapy and Outcomes Science Loma Linda University, School of Pharmacy Loma Linda, California
7/2009 - 6/2010	Professor, Pharmacy Practice and Administration (Tenured) Western University of Health Sciences, College of Pharmacy Pomona, California
2008- Present	Clinical Professor of Medicine California College of Medicine University of California, Irvine Irvine, California
6/2003 - 7/2009	Associate Professor of Pharmacy Practice and Administration (Tenured) Western University of Health Sciences, College of Pharmacy Pomona, California
2001- 2009	Associate Clinical Professor School of Pharmacy University of California, San Francisco
1998- 2008	Associate Clinical Professor of Medicine California College of Medicine, University of California, Irvine Irvine, California

9/1997 - 6/2003	Associate Professor of Pharmacy Practice (Tenure-Track) – Founding Faculty Western University of Health Sciences, College of Pharmacy Pomona, California
1990- 1998	Assistant Clinical Professor of Medicine California College of Medicine University of California, Irvine
1987- 2001	Assistant Clinical Professor School of Pharmacy University of California, San Francisco

Pharmacy Practice Experience

7/2011 - 3/2013	Director Oral Chemotherapy Management Clinic Loma Linda University Cancer Center Loma Linda, California
1/2002- 6/2010	Faculty-in-residence Hematology-Oncology Medical Group of Orange County, Inc Orange, California
10/2006 - 10/2009	Advisor, Research Program Center for Cancer Prevention and Treatment, St. Joseph Hospital Orange, California
9/1997 - 4/2002	Associate Clinical Professor of Medicine and Pharmacy Practice Faculty-in-residence Chao Family Comprehensive Cancer Center University of California, Irvine
7/1995 - 7/2003	Expert Examiner Competency Committee California State Board of Pharmacy
2/1992 - 8/1997	Oncology Pharmacist Specialist & Cancer Center Pharmacist-in-Charge University of California, Irvine Medical Center Orange, California
12/1989- 2/1992	Oncology Senior Pharmacist University of California, Irvine Medical Center Orange, California
8/1987- 12/1989	Oncology Clinical Pharmacist University of California, Irvine Medical Center Orange, California
3/1986 - 6/1986	Intern Pharmacist Caremark Home Health Care Irvine, California
1983-1985	Intern Pharmacist Pacific Presbyterian Hospital San Francisco, California

Education

1986-1987	University of California, Irvine Medical Center Orange, California	Resident in Clinical Pharmacy
1982-1986	University of California, San Francisco School of Pharmacy San Francisco, California	Doctor of Pharmacy
1979-1982	University of California, Los Angeles Los Angeles, California	Bachelor of Science Biochemistry
1977-1979	Santa Ana College Santa Ana, California	Associate of Science Biological Science

Licensure

1986-Present	State of California Licentiate in Pharmacy License Number: RPH40354
--------------	--

Honors and Awards

2009	Western University College of Pharmacy Preceptor of the Year Award
2008	Western University College of Pharmacy Faculty Service Award
1999	1998 Orange County Society of Health System Pharmacists Pharmacist of the Year Award
1998	American Society of Health-System Pharmacists Practitioner Recognition Award
1996	UCI Incentive Award (Bone Marrow Transplantation Program)
1995	University of California, San Francisco School of Pharmacy Preceptors of the Year Award
1993	California Society of Hospital Pharmacists Practitioner Recognition Award
1991	UCI A&PS Achievement Award
1991	UCI A&PS Development Award
1990	UCI A&PS Achievement Award

Memberships in Professional Organizations

2010-Present	Multi-National Association of Supportive Cancer Care (MASCC)
2007-Present	American Association of College of Pharmacy (AACP)
2004-Present	Hematology Oncology Pharmacy Association (HOPA) – Founding Member
2003-Present	California Society of Health-System Pharmacists (CSHP)
2001-2011	American College of Clinical Pharmacy (ACCP)
1997-2000	American Association of College of Pharmacy (AACP)
1994-2006	Southern California Oncology Pharmacy Group (SCOPG) – Founding Chair
1994-Present	Southwest Oncology Group (SWOG) – Founding Chair of Pharmaceutical Sciences Committee
1993-Present	American Society of Clinical Oncology (ASCO)
1986-2001	California Society of Health-System Pharmacists (CSHP)
1986-2010	American Society of Health-System Pharmacists (ASHP)

TEACHING**Residents and Fellowship Programs**

2012-2013	Oncology Pharmacy Specialty Resident (PGY2) Zahra Azazbahi, PharmD Oral Chemotherapy Management Clinic (8 weeks + longitudinal) Preceptor Loma Linda University and Medical Center
2011-2012	Oncology Pharmacy Specialty Resident (PGY2) Cham Nguyen, PharmD Oral Chemotherapy Management Clinic (8 weeks + longitudinal) Preceptor Residency Project Mentor Loma Linda University and Medical Center
2006-2010	Oncology Pharmacy Fellowship Western University of Health Sciences & St. Joseph Hospital Cancer Institute 2006-2007 Fellow: Tim C Chen, PharmD, BCPS http://www.westernu.edu/bin/pharmacy/pharmacy-newsletter-winter-2010.pdf 2008-2010 Fellow: Vuong Green, PharmD, BCOP
1991-1995	Chao Comprehensive Cancer Center Oncology Fellows Division of Hematology/Oncology Department of Medicine University of California, Irvine
1987-2002	Pharmacy Residents (PGY1) Inpatient and Outpatient Oncology Rotation University of California Irvine, Medical Center

Didactic Curriculum

Chapman University School of Pharmacy

Year	Course	Role	Hours Taught	Title of Lecture
Fall 2014 - Present	Master of Science in Pharmaceutical Sciences Program – PHS602 Drug Discovery and Development	Co- Lecturer	4.5	Clinical Trials
Fall 2016	Pharmacogenomics and Personalized Medicine	Course Coordinator	2 credit units	

Brandman University

Year	Course	Role	Hours Taught	Title of Lecture
Fall 2014	Doctor of Nursing Practice Specialty Core Courses	Lecturer	3	Pain and Pain Management (CPE of NP Controlled Substance Furnishing) – recorded lecture

University of California, Irvine

Year	Course	Role	Hours Taught	Title of Lecture
Spring 2011- Present	Bachelor Program Elective: Biology of Cancer	Lecturer	2	Anti-Cancer Therapeutics
Spring 2014 - Present	School of Medicine, 2 nd year: Med Pharm	Lecturer	3-4	Pharmacology of Anti-Cancer Therapeutics

Loma Linda University School of Pharmacy

Year	Course	Role	Hours Taught	Title of Lecture
2010-2012	IPDM XI	Course Facilitator & lecturer	30 (2 Credit Hours)	Oncology and Transplant
Spring 2012	IPDM X	Lecturer	1	Highlights on Literature Evaluations of Different Study Designs
Spring 2012	Independent Study	Advisor	1 Credit Unit (1 student)	Outcome Analysis of Oral Chemotherapy Clinic
Spring 2011	Independent Study	Advisor	6 Credit units (4 students)	Lung Cancer Research Projects
Spring 2011	Elective	Lecturer	4	Pain Management – Case-Based

Western University College of Pharmacy

Year	Course	Role	Hours Taught	Title of Lecture
2009-2010	IPE5100	Course Facilitator	1 Credit Unit	Patient Centered Cases - An Interprofessional Approach
2009-2010	5302	Lecturer	2	Clinical Pharmacogenomics in Oncology
2007-2010	6210	Course Facilitator		Integrative Block
2007-2010	6210	Case Facilitator	53	Case Discussion Facilitator
1998-2008	6303	Course Facilitator	56	Hematology & Oncology
2008-2010	6303	Lecturer	20	Introduction to Cancer, Cancer Management and Cancer Prevention Pharmacology of Cancer Therapeutics & case study Management of Hematologic Complications & case study Cancer Pain Management & case study Colon Cancer Lung Cancer
1998-2008	Hem/Oncology	Lecturer	88	Introduction to Cancer, Cancer Management and Cancer Prevention Review of Hematopoiesis and Clinical Database Pharmacology of Cancer Therapeutics & case study Management of Hematologic Complications & case study Gastrointestinal Complications - Nausea/Vomiting & case study Gastrointestinal Complications – Mucositis, Diarrhea, Constipation, and Nutrition & case study Genitourinary Complications & case study Hypersensitivity Reactions, Cardiotoxicity, and Pulmonary Complications & case study Cancer Pain Management & case study
1998-2010	Neurology	Lecturer	12-18	Pain Management
2002	First yr OTC	Lecturer	2	OTC - Constipation

2001-03	1.5	Lecturer	1	Overview of Hematopoietic System
2001	6209	Lecturer	1	Effect of Aging on the Hematopoietic System
2000	1.4	Lecturer	4	Immunotherapeutic Agents in Oncology
1999-02	2.5 or 2.10	Lecturer	2	Investigational Drugs
1999-02	2.5 or 2.10	Lecturer	4	Sterile Products

University of California, Irvine – Others

<u>Date</u>	<u>Role in Course</u>	<u>Hours Taught/year</u>	<u>Title of Course/Lecture</u>
	Lecturer (Annual):		
1997-	Hematology/Oncology	8	Clinical Pharmacology of Anti-Cancer
Present	Fellowship Program		Therapeutics/Essentials to Writing
1999-	Gynecology/Oncology	2-6	Chemotherapy Order
Present	Fellowship Program		

Loma Linda University – Others

<u>Date</u>	<u>Role in Course</u>	<u>Hours Taught</u>	<u>Title of Course/Lecture</u>
	Lecturer:		
7/2011-2013	New faculty & Post-doc training program	2	Study Design – How to get your research started?
4/28/2011	PA Program	3	Clinical Pharmacology of Anti-Cancer Therapy
4/19/2012	PA Program	4	
4/17/2013	PA Program	4	
2/2013	Hematology/Oncology Fellowship Program	2	Clinical Pharmacology

Western University - Others

<u>Date</u>	<u>Role in Course</u>	<u>Hours Taught</u>	<u>Title of Course/Lecture</u>
2002	Lecturer	0.5	Clinicopathological Exercise #3: Breast Cancer
2000	Lecturer	3	College of Osteopathic Medicine Blood and RE Systems: Pharmacology of Cancer Chemotherapeutics

Clerkship

Loma Linda University

<u>Date</u>	<u>Role</u>	<u>Title of Program</u>	<u>Number of Students per Year</u>
2012-2013	Preceptor	APPE	3
2012-2013	Preceptor	IPPE	2
2011-2012	Preceptor	APPE Ambulatory Care or Oncology Elective	9
2011-2012	Preceptor	IPPE	4

Western University College of Pharmacy

<u>Date</u>	<u>Role</u>	<u>Title of Program</u>	<u>Number of Students per Year</u>
1999-2010	Preceptor	Oncology APPE	8-16
		Ambulatory Clinical (AC) or Selective elective (SE)	
2006-2010	Preceptor	Oncology APPE	8
		Inpatient experiential (IX)	
2000-2010	Preceptor	Oncology Advanced Elective	1-4

Others

<u>Date</u>	<u>Role</u>	<u>Title of Program</u>	<u>Number of Students</u>
2009	Visiting Professor	Kobe Gakuin University, Japan Elective Course: Lung Cancer Management – a Pharmacist Role	22
2002	Preceptor	Kansas University Non-traditional PharmD Program Oncology rotation	1
2001	Preceptor	Hong Kong Clinical Pharmacist Training Program at UCIMC	2
2000	Coordinator/ Lecturer/ Clinical Preceptor	Oncology Pharmacy Care Training Program in Hong Kong	18
1987 - 2001	Preceptor	UCSF School of Pharmacy Oncology Clerkship rotation	>30

ADVISING ACTIVITY**Chapman University School of Pharmacy Research Advisor**

<u>Year</u>	<u>Students</u>
2014-2016	Noroozi Mahjabin (co-advisor: Hamidreza Montazeri Aliabadi, PharmD, PhD)

Loma Linda University School of Pharmacy Faculty Advisor

<u>Year</u>	<u>Number of students</u>
2011-2012	13

Loma Linda University School of Pharmacy Research Project

<u>Year</u>	<u>Number of students/Resident</u>
2012-2013	3
2011-2012	2
2010-2011	7
2011-2012	3

Western University College of Pharmacy Special Project

<u>Year</u>	<u>Name of Project</u>
2009-2010	CSHP Student Chapter Cancer Awareness Outreach Program
2010	AACP Faces of Change for Pharmacy Practice Video

Western University Team Advisor

<u>Year</u>	<u>Number of Team/Year</u>	<u>Number of Members per Team</u>
1997-Present	1-2 team	8

Western University Research Students

<u>Year</u>	<u>Number of student per year</u>
1998-Present	1-2

Undergraduates/High School

<u>Year</u>	<u>Number of student</u>
2011	1
2008	1
2007	2
2005	1
2003	1
2002	1
1997	1

Major Innovative Services, Programs and Courses Established

2014	SWOG Pharmacogenomic Initiative (Collaborator: Susan Kalbular, PhD)
2014	SWOG Patient Education Handout (Pharmaceutical Science Committee)

2011 LLU Cancer Center Oral Chemotherapy Management Clinic
 2010 LLU Medical Center Oncology Pharmacy OPTIMUM Group
 2010 LLU School of Pharmacy Chart Note Grading Rubrics Assessment Project
 2009 SWOG Pharmacist Protocol Review Program
 2009 Southwest Oncology Group IND Policy and Procedures for Dietary Supplement
 2008 Southwest Oncology Group Investigational Drug Database
 2008 Southwest Oncology Group Pharmacist Liaison Program
 2007 Hematology Oncology Pharmacy Association (HOPA) Research Network
 2006 St. Joseph Hospital Health Care Provider Smoking Cessation Training Program - Consultant
 2006 St. Joseph Hospital Oncology Nursing Drug of the Month Education Program
 2006 Southwest Oncology Group Investigational Drug Handling Training Program Website
<http://swog.org/visitors/newsletters/2009/10/video.htm>
 2006 Pharmacy Co-op Group Drug Information Website
 2005 The Society of Hospital Pharmacist of Hong Kong Pain Management Initiative
 2002 Southwest Oncology Group Drug Information Web Site
 2001 Western University of Health Sciences and Hong Kong International Exchange Program
 2000 Hong Kong Basic Oncology Pharmaceutical Care Pharmacist Training Program
 2000 Western U of Health Sciences College of Osteopathic Medicine Cancer
 Chemotherapy Pharmacology Course
 1999 UCI Gynecology/Oncology Fellowship Annual Chemotherapy Core Course (2-6 hrs)
 1998 Western U of Health Sciences College of Pharmacy Hematology/Oncology Block Facilitator
 1998 UCI Oncology Nursing Drug of the Month Lecture Series
 1997 Western U of Health Sciences College of Pharmacy Pain Management Lectures
 1997 Western U of Health Sciences College of Pharmacy Investigational Drug Handling Lecture
 1997 Western U of Health Sciences College of Pharmacy Patient-Based Program Faculty Planning Core
 Group
 1997 UCI Hematology/Oncology Fellowship Annual Chemotherapy Core Course (8 hrs)
 1997 Southwest Oncology Group Investigational Drug Handling Workshop
 1997 UCI Bone Marrow Transplantation Nursing Certification Course
 1996 Southwest Oncology Group Investigational Drug Accountability Quality Assurance Program
 1993 UCI Hematology/Oncology Interdisciplinary Lecture Series
 1992 UCI Oncology Nursing Drug of the Month Lecture Series
 1991 UCI Division of Hematology/Oncology Fellowship Pharmacy Rotation
 1989 UCI Oncology Pharmacy Program Investigational Drugs Services
 1987 University of California, Irvine Medical Center Pharmacy Resident Clinical Clerkship in Oncology-
 Outpatient and Inpatient
 1987 University of California, San Francisco School of Pharmacy Elective Clinical Clerkship in Oncology at
 UCIMC

PROFESSIONAL ACTIVITIES

Services to Professional, Scholarly, Scientific, Educational and Governmental Agencies and Organizations

2014 Hematology Oncology Pharmacy Association (HOPA)
 2014 Research Grant Reviewer
 2013 National Board of Pharmacy Competency Statement Revision Task Force
 2012-2014 National Cancer Institute (NCI) Symptom Management and Health-Related Quality
 of Life Steering Committee (SxQOL) Drug Development Task Force (DDFT) – co-
 chair (with Joanna Brell, M.D., NCI)
<http://transformingtrials.cancer.gov/steering-committees/symptom-management>
 2011-2013 2011 making the NCI Informed Consent Template More Concise Task Force -
 member
 2011-Present Associate Member, Chemical Structural Biology Research Program
 University of California, Irvine Chao Family Comprehensive Cancer Center

2011-Present	Member, UCI Center for Drug Discovery and Development University of California, Irvine
2010-2012	Orange County Society of Health System Pharmacists Board of Directors (2010-2012) Delegates to CSHP (2010-2011)
2008-2009	Hematology Oncology Pharmacy Association (HOPA) – member, Research Committee (Founding Chair) Research Network Subcommittee – Founding Chair Annual Meeting Abstract Reviewer Best Practice Symposium Research Program Advisor
2007-2008	Hematology Oncology Pharmacy Association (HOPA) – member, Research Committee Research Network Task Force Leader Annual Conference Research Network Townhall meeting – Facilitator Annual Conference Professional Affairs Network Forum – Facilitator
2004-2007	Hematology Oncology Pharmacy Association (HOPA) – Founding Chair, Research Committee 2007 HOPA Research Network - Founder 2007 Annual Meeting Research Workshop – Facilitator 2007 Annual Meeting Abstract Reviewer 2007 Annual Meeting Poster Judges 2006 Annual Meeting Abstract Reviewer 2006 Annual Meeting Poster Judges 2005 Practitioner Award Program - Founder 2005 Annual Meeting Abstract Reviewer 2005 Annual Meeting Poster Judges
2001	Southern California College of Clinical Pharmacy (SCCCP) Awards Selection Committee
2000-2001	California Society of Health-System Pharmacists Focus 2001 Continuing Education Symposium Co-Chair
1998-1999	California Society of Health-System Pharmacists Practitioner Recognition Credentialing Committee
1997-1998	California Society of Health-System Pharmacists Task Force on Non-Traditional Roles in HealthCare for Pharmacists
1997-2000	Orange County Society of Health-System Pharmacists - Board of Directors
1997	Orange County Society of Health-System Pharmacists - Continuing Education Committee
1997	Orange County Society of Health-System Pharmacists - Strategic Planning Committee Chairperson
1995-2003	California State Board of Pharmacy Competency Committee
1994-2000	Southern California Oncology Pharmacy Group – Founding Chair
1994-Present	Southwest Oncology Group (SWOG), 1994-Present Pharmaceutical Sciences Committee - Founding Chair 2008-Present Pharmacist Liaison to Cancer Control & Prevention Committee 2008 – Present Leader of Pharmaceutical Sciences 2009 – Present Conflict Management Committee – member\ 2009 – Present Quality Initiative Committee 2009 – Present Young Investigator Workshop Trainer and Mentor 2009 – Present Young Investigator Award Selection Task Force 2011 SWOG Development Award – reviewer 2014 – Present Latin American Initiative Task Force
1996-Present	Southwest Oncology Group (SWOG) Drug Information Subcommittee – Founder
1994-1996	Orange County Society of Health-System Pharmacists - Immediate-Past President, President, President-Elect
1991	California Society of Health-System Pharmacist (CSHP) Continuing Education Committee for Seminar 91'

1991-1993	Orange County Society of Health-System Pharmacists - Board of Directors
1989, 90 & 92	Orange County Society of Health-System Pharmacists - Delegate to California Society of Hospital Pharmacists
1988-1992	Orange County Society of Health-System Pharmacists - Chair of Education and Training Committee

Service to Professional Publications

2015	The Annals of Pharmacotherapy – Manuscript Reviewer
2013	Journal of Hematology & Oncology Pharmacy – Manuscript Reviewer
2013	Expert Opinion on Biological Therapy – Manuscript Reviewer
2012	ASHP Guidelines on Preventing Medication Errors with Chemotherapy and Biotherapy - Reviewer
2012	Drug Safety – Manuscript Reviewer
2010	Asian Journal of Pharmaceutics – Manuscript Reviewer
2010	Journal of Hematology and Oncology – Manuscript Reviewer
2009	Current Drug Discovery Technologies” (CDDT) – Manuscript Reviewer
2009	Case Journal – Manuscript Reviewer
2009	Cancer – Manuscript Reviewer
2009	Journal of Experimental and Clinical Cancer Research – Manuscript Reviewer
2008-2013	Gastrointestinal Cancer Review Letters (GCRL) - Editorial Board Member
2008	Phytotherapy Research – Manuscript Reviewer
2007	World Journal of Surgical Oncology – Manuscript Reviewer
2007	Melanoma Research – Manuscript Reviewer
2006	The Lancet – Manuscript Reviewer
2006	American Journal of Health-System Pharmacists – Manuscript Reviewer
2006	Pharmacotherapy Principles and Practice – Chapter Reviewer
2003	American Society Health System Pharmacists Basic Concept in Oncology – Book Reviewer
2001	American Society of Health System Pharmacists ASHP’s PharmPrep – Book Reviewer
1992-1995	American Journal of Obstetrics & Gynecology- Manuscript Reviewer
1994-2000	Southern California Oncology Pharmacy Group Newsletter – Reviewer
1994-1997	Southwest Oncology Group Newsletter Pharmacy Column Editor

Grant Reviewer

2005	Cancer Research UK Clinical Trials Awards and Advisory Committee “A Phase II study of gemcitabine and bexarotene (GemBex) in the treatment of cutaneous T-cell lymphoma”
2005 – Present	UICC Expert Reviewer Panel for Fellowship Applications

Community and Public Service

Spring 2010	Genesha High School Skin Cancer Awareness Outreach
March 2010	Century High School Healthcare Career Awareness Outreach
2009-2012	Orange County Medical Reserve Corp Volunteer
2005-2009	St. Joseph Hospital Cancer Institute Lung Cancer Patient Support Group
2005-2009	St Joseph Hospital Cancer Institute Melanoma Patient Support Group
2005-2007	El Modena High School Education Foundation Board Member
2006-2007	El Modena High School Library Expansion Subcommittee member
August 2005	Fountain Valley Breast Cancer Support Group
2004	UCIMC Melanoma Patient Support Group
1999-2001	UCIMC Ovarian Cancer Patient Support Group
1999-2007	UCIMC Melanoma Patient Support Group
1993, 95	Orange County Society of Health-System Pharmacists Poison Prevention Display

1990-1994

UCIMC Clinical Cancer Center Public and Professional Committee

Consultantships/Speaker Bureau

2013	Teva Pharmaceuticals, INC
2007	Pharmion, Inc.
2006	Amgen Inc. – Curriculum Development Advisory Board
2005-2006	INCE CME Curriculum Development Advisory Board
2005	Abraxis Inc.
2004-2007	Medsite
2004-2008	Elan Pharmaceuticals, Inc
2003-2008	Innovative Medical Communications
2003-2005	MGI Pharma
2003-2008	Bristol Myers Squipps Oncology
2003-2007	Millennium Pharmaceuticals, Inc
2003	AstraZeneca LP
2002-2005	Merck Inc
2002-2008	Amgen Inc.
2001-2010	The Council of Healthcare Advisors
2000-2001	Health Dimensions Inc. – Clinical protocol development and professional writing
1997	US Bioscience- Hexalan package insert
1997	Southwest Oncology Group - Body Surface Area Treatment Guidelines
1996	Southwest Oncology Group - Investigational Drug Handling Video
1996	Rhone Poulenc Rorer - Taxotere package insert
1993	I-Flow Infusion Co. - ambulatory infusion pump

Invited Lectures/Seminars

International

11/93	Yunnan Provincial Science and Technology Department, Peoples Republic of China Invited Lecturer “New Drugs in Oncology” “New Technology in Administering Oncologic Medicines”
01/00	The Pharmaceutical Society of Hong Kong and The Society of Hospital Pharmacists of Hong Kong “Management of Chemotherapy-induced Nausea and Vomiting”
01/00	The Pharmaceutical Society of Hong Kong and The Society of Hospital Pharmacists of Hong Kong Chemotherapy Order Evaluation and Basic Oncology Patient Care by a Pharmacist”
01/00	The Chinese University of Hong Kong, School of Pharmacy “Introduction to Cancer Management”
09/01	The 61 st World Congress of Pharmacy and Pharmaceutical Sciences 2001 - Singapore International Pharmaceutical Federation (FIP) “Acceptance of Far Eastern Medicine in “Modern” Societies”
04/05	The 18 th Annual Meeting of the Society of Hospital Pharmacists in Hong Kong “Pain Management in a Cancer Patient – a Case-Based Program”
06/08	The HOPA/ISOPP 2008 Conference in Anaheim, California “Step by Step Guide to Doing a Research Project”

- 06/08 The HOPA/ISOPP (Hematology Oncology Pharmacy Association/International Society of Oncology Pharmacy Practice) 2008 Conference in Anaheim, California
“Research Practice Model”
- 07/09 Kobe City Hospital Pharmacy Department, Kobe, Japan
“Lung Cancer Practice Model: Assessment and Management”
- 07/09 Kobe Gakuin University College of Pharmacy, Kobe, Japan
“Longitudinal Pharmacy Curriculum Development and Management of Student Issues”
- 11/10 Hong Kong Pharmaceutical Care Foundation, Hong Kong, PRC
“Oral Targeted Anti-Cancer Agents: Patient Management”
- 06/13 Hong Kong Chinese University School of Pharmacy, Hong Kong, PRC
“Integration of Teaching, Clinical Service, and Research – The 6-degree of Kevin Bacon”

National

- 10/96 “New Drugs Update”
Southwest Oncology Group Meeting, Chicago, Illinois (0.5 CE)
- 4/97 “Handling Research Drugs”
Southwest Oncology Group Meeting, Dallas, Texas (1.0 CE)
- 4/97 “New Drugs Update”
Southwest Oncology Group Meeting, Dallas, Texas (0.5 CE)
- 10/97 “Update of Oncologic Drugs”
Southwest Oncology Group Meeting, Seattle, Washington (0.5 CE)
- 4/98 “Pharmacology in Chemoprevention Trials”
Southwest Oncology Group Meeting, Atlanta, Georgia (0.5 CE)
- 10/98 “Pain Medication Dosing Conversion”
Southwest Oncology Group Meeting, San Antonio, Texas (0.5 CE)
- 10/98 “Pharmacologic Management of Cancer Pain”
Southwest Oncology Group Meeting, San Antonio, Texas (0.5 CE)
- 10/99 “Handling Research Drugs”
Southwest Oncology Group Meeting, San Diego, California (1.0 CE)
- 04/00 “Handling Research Drugs”
Southwest Oncology Group Meeting, Seattle, Washington (1.0 CE)
- 10/00 “Handling Research Drugs”
Southwest Oncology Group Meeting, New Orleans, Louisiana (1.0 CE)
- 10/00 “Cancer and the Elderly Patients”
Southwest Oncology Group Meeting, New Orleans, Louisiana (0.5 CE)
- 4/02 “New Drugs in Oncology”
Southwest Oncology Group Meeting, Dallas, Texas (0.5 CE)
- 9/02 “Supportive Care in an Oncology Patient”

- Northeast Florida Society of Health System Pharmacists, Florida (1.0 CE)
- 10/02 “Pharmacology of Oxaliplatin and Iressa”
Southwest Oncology Group Meeting, San Antonio, Texas (0.5 CE)
- 12/02 “Epidemiology and Pathophysiology of Chemotherapy-Induced Nausea and Vomiting”
University of New Mexico Cancer Center, New Mexico (1.0 CE)
- 02/03 “Role of New Hematopoietic Growth Factors in the Management of Cancer Patients – A Case-based Program”
New Drugs and Pharmacotherapy Symposium
University of Pacific, College of Pharmacy
Lake Tahoe, Nevada (1.0 CE)
- 04/03 “S0413 – Epratuzumab in non-Hodgkin’s Lymphoma”
Southwest Oncology Group Meeting, San Diego, California (0.5 CE)
- 04/03 “New Drugs in Oncology”
Southwest Oncology Group Meeting, San Diego, California (0.5 CE)
- 08/03 “Update on Darbepoetin Alfa “
Amgen Speaker Training Program, Laguna Beach, California
- 10/03 “What is the Role of Granulocyte Colony Stimulating Factor in the Treatment of Leukemia?”
Southwest Oncology Group Meeting, Seattle, Washington (0.5 CE)
- 10/03 “New Drugs in Lung Cancer”
Southwest Oncology Group Meeting, Seattle, Washington (0.5 CE)
- 03/04 “Updates in Lung and Colon Cancer – a Case-Based Program”
New Drugs and Pharmacotherapy Symposium
University of Pacific, College of Pharmacy
Lake Tahoe, NV (1.0 CE)
- 04/04 “Radioimmunotherapy – Zevalin”
Southwest Oncology Group Meeting, San Diego, California (0.5 CE)
- 04/04 “New drug in Oncology”
Southwest Oncology Group Meeting, San Diego, California (0.5 CE)
- 10/04 “Antisense Therapy in Melanoma”
Southwest Oncology Group Meeting, Kansas City, Missouri (0.5 CE)
- 10/04 “Evolution of the Taxanes”
Southwest Oncology Group Meeting, Kansas City, Missouri (0.5 CE)
- 09/05 “Appropriate Prescribing of Colony Stimulating Factors: Risk Assessments”
Association of Community Cancer Center 25th Annual Meeting, Portland, Oregon (1.0 CE)
- 09/05 Updates on Darbepoetin Alfa:
“Updates on every 2 week dosing of Aranesp in chemotherapy-induced anemia”
“Updates on every 3 week dosing of Aranesp in chemotherapy-induced anemia”
“Updates on Aranesp in the treatment of anemia of cancer”
“Updates of Aranesp in Myelodysplastic Syndrome”
Amgen Speaker Training Program, San Diego, California

- 10/05 “Pharmacology of Rituximab and Bevacizumab”
Southwest Oncology Group Meeting, Dallas, Texas (0.5 CE)
- 10/05 “Updates on Herceptin in Adjuvant Breast Cancer”
Southwest Oncology Group Meeting, Dallas, Texas (0.5 CE)
- 04/06 “BAY 43-9006 and It’s Use in Multiple Trials”
Southwest Oncology Group Meeting, Salt Lake City, Utah (0.5 CE)\
- 08/06 “Frequently Asked Questions”
Amgen Speaker Training Program, Atlanta, Georgia
- 10/06 “New Targeted Drugs: Are They Identical or Fraternal”
Southwest Oncology Group Meeting, Seattle, WA (0.5 CE)
- 10/06 “Introduction to a New EGFR Inhibitor: Panitumumab (Vectibix™)”
Midwest Regional Multidisciplinary Lecture Series (MI, OH)
- 05/07 “Targeted Therapy: Bortezomib (Velcade) and Sorafenib
Southwest Oncology Group Meeting, Chicago, IL (0.5 CE)
- 05/07 “Updates on the Management of EGFR Inhibitors-induced Skin Rash”
Southwest Oncology Group Meeting, Chicago, IL (0.5 CE)
- 06/07 “Mechanism of Velcade (Bortezomib)
EPIC Speaker Training Program, Chicago, IL
- 10/07 “Management of Chemotherapy-induced Neurotoxicity”
Southwest Oncology Group Meeting, Huntington Beach, CA (0.5 CE)
- 05/08 “Dasatinib and S0622”
Southwest Oncology Group Meeting, Atlanta, Georgia (0.5 CE)
- 05/08 “Individualized Treatment in Breast Cancer”
Southwest Oncology Group Meeting, Atlanta, Georgia (1 CE)
- 10/08 “Symptom Management of Oral Targeted Agents”
Southwest Oncology Group Meeting, Chicago, IL (0.5 CE)
- 03/09 “Use of Biomarkers in Community Practice”
National Comprehensive Cancer Network (NCCN) Best Practices in Oncology Pharmacy Management
Program: NCCN 14th Annual Conference: Clinical Practice Guidelines and Quality Cancer Care.
Hollywood, Florida (3 CE for the symposium)
- 04/09 “Biomarkers and Anti-Cancer Therapy in Gastrointestinal Cancer”
Southwest Oncology Group Meeting, San Francisco, CA (0.5 CE)
- 09/09 “Pharmaceutical-related Issues in Protocol Development”
Southwest Oncology Group Young Investigator Workshop, Seattle, Washington.
- 10/09 “Use of Erlotinib in Lung Cancer Patients”
Southwest Oncology Group Meeting, Chicago, IL (0.5 CE)
- 10/09 “Clinical Trial Management: Research Drug Issues”
Southwest Oncology Group Meeting, Chicago, IL (0.5 CE)
- 04/10 “Cognitive Impairment in Cancer Patients”
Southwest Oncology Group Meeting, San Francisco, CA (1.0 CE)

- 04/10 “Nutritional Supplements: Regulatory Parameters”
Harry E. Haynes Cancer Control and Prevention Symposium
Southwest Oncology Group Meeting, San Francisco, CA
- 09/10 “Pharmaceutical-related Issues in Protocol Development”
Southwest Oncology Group Young Investigator Workshop, Seattle, Washington.
- 10/10 “Clinical Pharmacology Updates in Breast Cancer Treatments”
Southwest Oncology Group Meeting, Chicago, IL (1.0 CE)
- 4/11 “Clinical Pharmacology Updates in Lung Cancer Treatment”
Southwest Oncology Group Meeting, San Francisco, CA (1.0 CE)
- 10/11 “Role of Metformin in Breast Cancer Prevention”
Southwest Oncology Group Meeting, San Antonio, TX (1.0 CE)
- 10/12 “EGFRI and Dermatologic Toxicity”
Southwest Oncology Group (SWOG) Meeting, Chicago, IL (1.0 CE)
- 5/13 “Drug Interactions Associated with Oral Chemotherapeutic Agents: Patient Management”
Jeri and Noburu Oishi Symposium
SWOG Group Meeting, San Francisco, CA (1.0 CE)
- 5/13 “S1207: Review of Everolimus”
Oncology Research Professionals Continuing Education Workshop
SWOG Group Meeting, San Francisco, CA
- 9/2010 “Pharmaceutical-related Considerations in Protocol Development”
Present SWOG New Investigator Training Workshop (Annual)
Seattle, WA

State

- 10/95 “Therapeutic Considerations in the Administration of Antineoplastic Chemotherapy”
California Society of Hospital Pharmacist Annual Seminar Meeting. Palm Springs, California (1.0 CE)
- 3/96 “Management of Side Effects Induced by Narcotic Analgesics”
California Society of Health-Systems Pharmacist Annual Focus Symposium. Newport Beach, California (1.0 CE)
- 10/99 “Prostate Cancer”
California Pharmacist Association Western Education Fair, Anaheim, California (1.0 CE)
- 10/01 “Management of Prostate Cancer”
California Pharmacist Association Western Education Fair, Reno, Nevada (1.0 CE)
- 10/02 “Supportive Care in Oncology – a Case-Based Program”
California Society of Health System Pharmacists Seminar Pre-Symposium
University of Pacific, College of Pharmacy (3.0 CE)
- 03/03 “Role of New Hematopoietic Growth Factors in the Management of Cancer Patients – A Case-based Program”
New Drugs and Pharmacotherapy Symposium
University of Pacific, College of Pharmacy
San Francisco, California (1.0 CE)

- 04/04 "Updates in Lung and Colon Cancer – a Case-Based Program"
New Drugs and Pharmacotherapy Symposium
University of Pacific, College of Pharmacy
San Francisco, CA (1.0 CE)
- 11/04 "Risk Assessment in a Neutropenic Patient"
California Society of Health System Pharmacists Seminar Exhibitor's Theatre
Long Beach, CA (1.0 CE)
- 10/07 "Introduction to Oral Targeted Therapy in Cancer"
California Society of Health System Pharmacists Seminar 2007
Palm Springs, California (1.0 CE)
- 10/07 "Oral Targeted Anti-cancer Agents: Safe Handling and Patient Education"
California Society of Health System Pharmacists Seminar 2007
Palm Springs, California (1.0 CE)
- 11/11 "How to Recommend an Equianalgesic Dosing Regimen?"
California Society of Health System Pharmacists Seminar 2011
Anaheim, California (1.0 CE)
- 9/13 "Overview of Pharmacogenomics in Oncology"
Scripps 2013 33rd Annual Oncology Nurses Symposium
San Diego, California (1.0 CE)
- 10/13 "Patient Management in Oral Chemotherapy"
CSHP Foundation Symposium – "The Changing Paradigm of Cancer Care"
California Society of Health System Pharmacists Seminar 2013
Anaheim, California (1.0 CE)
- 10/13 "Managing ADRs in Oral Chemotherapy"
California Society of Health System Pharmacists Seminar 2013
Anaheim, California (1.0 CE)

Local

- 4/93 "Nutrition in Cancer Patients"
California State University in Pomona
- 10/93 "Handling of Cytotoxic Drugs"
Western Medical Center Pharmacy Department
- 6/96 "New Drugs in Oncology 1996"
Friendly Hills Medical Group Oncology Education Update (1.0 CE)
- 1989-2001 UCI Department of Medicine Grand Round Lecturer
- 1990-2001 UCI Department of Medicine Grand Round Lecturer
- 1990-2001 UCI Obstetrics/Gynecology Resident Annual Lecture Series Lecturer
- 1996 UCI Radiation Oncology Annual Lecture Series Lecturer

-2001

- 6/97 "New Drugs in Oncology 1997"
Friendly Hills HealthCare Network 1997 Education Update (1.0 CE)
- 2/98 "Clinical Pearls in Pain Management"
Orange County Society of Health-system Pharmacists (1.0 CE)
- 7/98 "Pain Management in the Elderly"
Geriatric Mini-Residency Pharmacy Program, Western U of Health Sciences (1.0 CE)
- 7/98 "Cancers in the Elderly"
Geriatric Mini-Residency Pharmacy Program, Western U of Health Sciences (1.0 CE)
- 10/98 "High-Dose Chemotherapy and Immunotherapy"
-2002 UCI Bone Marrow Transplantation Training Course
- 1998 "Supportive Care of Cancer Therapeutics"
-2003 UCI Gynecology Oncology Fellow Annual Lecture Series
- 10/01 "Drug Therapy for Breast, Ovarian, and Prostate Cancer"
UCLA Intensive Course in Geriatric Medicine and Pharmacy Board Review (1.0 CE)
- 1/02 "Nausea and Vomiting in the Adult Oncology Patients"
UCI Gynecology Oncology Department, Orange, CA
- 4/02 "Challenging Cases in the Management of Cancer Patients"
The Southern California Oncology Practice Education Society (1.0 CE)
- 5/02 "Challenging Cases in the Supportive Care of Cancer Patients"
Southern California Federal Pharmacists Association (1.0 CE)
- 6/02 "Current Issues in Oncology and Supportive Care"
University of Pacific College of Pharmacy Continuing Education Program (2.0 CE)
- 12/02 "Epidemiology and Pathophysiology of Chemotherapy-Induced Nausea and Vomiting"
University of California, Irvine Medical Center, Department of Pharmaceutical Services
- 5/03 "Roles of the New Hematopoietic Growth Factors"
NeighborCare Pharmacy, Cerritos, California
- 7/03 "Updates on Management of Lung Cancers"
Wilshire/Los Angeles Society of Health Systems Pharmacists, Los Angeles, California (1.0 CE)
- 05/04 "Updates in the Management of Chemotherapy-induced Nausea and Vomiting"
University of California, Irvine Medical Center, Department of Gynecology Oncology
- 11/04 "Management of a Neutropenic Patient – a Case-Based Program"
Naval Hospital, San Diego, CA (1.0 CE)
- 5/05 "Update on Myeloid Growth Factors: Efficacy, Efficiency, and Outcomes"
Palm Spring Hospital Group
Rancho Mirage, CA
- 5/05 "New Guidelines for Hematopoietic Growth Factors"
Home Care Pharmacy and Nursing Group

Orange, California

- 6/05 “New Guidelines for Hematopoietic Growth Factors”
Home Care Pharmacy and Nursing Group
Chino, California
- 10/06 “Supportive Therapy in Oncology”
University of California, Irvine- Japanese Gynecology Oncology Group Clinical Exchange
Symposium on Gynecologic Oncology
Orange, California (1.0 CE)
- 11/06 “Introduction to a New EGFR Inhibitor: Panitumumab (Vectibix™)”
Southern California Multidisciplinary Lecture Series
- 11/06 “Adjunct Oncologic Agents and Supportive Care in Radiation Therapy”
University of California, Irvine Radiation Oncology Department
Orange, California (1.0 CE)
- 09/09 “Pharmacology and Supportive Care for Patients with Ovarian Cancer: Keys to success in writing chemotherapy orders”
University of California, Irvine Gynecology-oncology Fellow
Orange, California (3.0 hours)
- 03/09 “Incorporate Scholarship in Practice”
Western University of Health Sciences CAPE program
Pomona, California
- 04/09 “Pharmacology of Cancer Therapeutics in Ovarian Cancer”
University of California, Irvine Gynecology-Oncology Fellow
Orange, California (3.0 hrs)
- 04/09 “Pharmacology of Cancer Therapeutics in Ovarian Cancer”
University of California, Irvine Gynecology-Oncology Fellow
Orange, California (3.0 hrs)
- 09/09 “Pharmacology and Supportive Care for Patients with Ovarian Cancer: Keys to success in writing chemotherapy orders”
University of California, Irvine Gynecology-oncology Fellow
Orange, California (3.0 hours)
- 09/11 “Safe Handling of Anti-Cancer Medication and Beyond”
Orange County Society of Health Systems Pharmacist (OCSHP)
Fountain Valley, California (1.0 hour)
- 11/12 “Clinical Pearls of Pain Management: A Case-Based Approach”
Orange County Society of Health Systems Pharmacist (OCSHP)
Fountain Valley, California (1.0 hour)
- 11/15 “Management of Patients Receiving Oral Anti-cancer Targeted Therapy”
San Fernando Valley Society of Health Systems Pharmacist (SFVSHP) & PPSSFV: Night with Industry
Granada Hills, California (1.0 hour)

Papers and Posters Presented

1. "A Comparison of Two Methods to Predict Vancomycin Serum Concentrations in Neonates". Western States Residents and Preceptors Conference, 4/23/87, Asilomar, California. **Wong SF** (Platform Presentation)
2. "Ambulatory Pain Management by Pharmacists". California Society of Hospital Pharmacists (CSHP) Seminar 88', 10/14/88, Anaheim, California. Bullips T & **Wong SF**. (Poster Presentation)
3. "Pharmacists as the Primary Care Provider in Ambulatory Infusional Therapy". American Society Hospital Pharmacists (ASHP) Midyear Convention Poster Presentation, 12/5/88, Dallas, Texas. **Wong SF**, Bullips T, & Brown J. (Poster Presentation).
4. "Ambulatory Continuous Infusion Therapy: Complications and Adverse Reactions". International Consensus on Supportive Care in Oncology (ICSCO III), 8/24/90, Brussels, Belgium. Armentrout S & **Wong SF** (Poster Presentation).
5. "Neoadjuvant Chemotherapy with Cisplatin, Etoposide, and Continuous Infusional 5-Fluorouracil in the Treatment of Advanced Head and Neck Carcinoma". Congress on Neo-adjuvant Chemotherapy, 2/6/91, Paris, France. Armentrout S & **Wong SF**. (Poster Presentation).
6. "Continuous Infusional 5-Fluorouracil (5-FU) in the Treatment of Advanced Colorectal Cancer" American Society of Hospital Pharmacists 26th Annual Midyear Clinical Meeting, 1991, New Orleans, Louisiana. Le-Ta G, **Wong SF**, Kuo S, and Armentrout S. (Platform Presentation).
7. "Ambulatory Continuous Infusion Therapy: Complications and Adverse Effects". American Society of Hospital Pharmacists 26th Annual Midyear Clinical Meeting, 12/10/91, New Orleans, Louisiana. **Wong SF**, Ishida D, & Armentrout S. (Poster Presentation).
8. "Trans-retinoic Acid (tRA) in the Treatment of Recurrent Malignant Gliomas". Thirty -second Annual Meeting, American Society of Clinical Oncology, May, 1996. Atiba J, Jamil S, Meyskens FL, Cho J, Armentrout S, Berkson P, **Wong SF**, Neal J.(Poster Presentation) Proc.ASCO 15;2005a, 1996.
9. "Evaluation of the Cost-Effectiveness of Replacing IV Ondansetron (OND) with Oral Granisetron (GR) in Cisplatin (CDDP) - or Carboplatin (CARBO) - Chemotherapy" California Society of Health-System Pharmacists Seminar '97, 10/18/97, San Jose, California. **Wong SF**, Olgario R, & Ho B. (Poster Presentation)
10. "Evaluation of the Cost-Effectiveness of Replacing IV Ondansetron(OND) with Oral Granisetron (GR) in Cisplatin (CDDP)- or Carboplatin (CARBO)- Chemotherapy" American College of Clinical Pharmacy 1998 Spring Practice and Research Forum, Palm Springs, California. **Wong SF**, Olgario R, & Ho B. (Poster Presentation)
11. "The Control of Emesis Using a High Dose-Low Dose Regimen of Ondansetron in Children Undergoing Chemotherapy" American Society of Pediatric Hematology/Oncology Annual Meeting, September, 1998, Chicago, Illinois. Moore J, **Wong SF**, & Zeltzer P. (Poster Presentation).
12. "Laser Effect on Oral Mucositis in Patients Receiving Chemotherapy" American Society of Clinical Oncology Annual Meeting, May 1999, Atlanta, Georgia. Wilder-Smith P, **Wong SF**, Ku N, & Kurosaki T. (Poster Presentation)
13. "Pharmacoeconomics Analysis of IV Ondansetron vs. Oral Granisetron in Conditioning Regimens" International Bone Marrow Transplant Registry/Autologous Blood and Marrow Transplant Registry Annual Meeting, March 2000, Anaheim, California. **Wong SF**, Law A, Chau HV, Keuroghelian S, Lim S, & Ho W. (Poster Presentation)
14. "Evaluation of Diagnosis and Treatment of Depression in Breast Cancer Patients" American Society of Health System Pharmacists Midyear Meeting, December 2000, Las Vegas, California. Lim D, Chau HV, Franson K, Osann K, & **Wong SF**. (Student Poster Presentation)
15. "Evaluation of Diagnosis and Treatment of Depression in Breast Cancer Patients" Pharmacy Student Research Conference – Western Region, June 1, 2001, Boulder, Colorado. Lim D, Chau HV, Franson K, Osann K, & **Wong SF**.
16. "Physician Satisfaction Survey in Assessing a Revised Hamilton Depression Checklist". Pharmacy Student Research Conference – Western Region, June 1, 2001, Boulder, Colorado. Chau HV, Chen J, Lim D, Franson K, & **Wong SF**
17. "Implementation of an Assessment Method for the Recognition of Depression in Cancer Patients" American College of Clinical Pharmacy 2002 Spring Practice and Research Forum, Savannah, Georgia. Chau HV, Lim D, Franson K, & **Wong SF** (Poster Presentation)

18. "Southwest Oncology Group Pharmacy Committee." National Cancer Institute, July 2003, Washington DC, Maryland. **Wong SF**. (Poster Presentation)
19. "Clinical and Economic Outcomes of a Formulary Change from Filgrastim (G-CSF) To Sargramostim (GM-CSF) in Patients Receiving Myelosuppressive Chemotherapy." American College of Clinical Pharmacy 2002 Fall Annual Meeting, Albuquerque, New Mexico. Chan Holly & **Wong SF** (Poster Presentation)
20. "Retrospective Study of the Appropriate Utilization of Epoetin alfa and Darbepoetin alfa in Cancer Patients with Anemia." American College of Clinical Pharmacy 2004 Fall Annual Meeting, Dallas, Texas. **Wong SF**, Brown M, and Sarakain R. (Poster Presentation)
21. "Prospective Surveillance of Delayed Chemotherapy-induced Nausea and Vomiting (CINV) in a Private Practice Oncology Office". American Society of Health System Pharmacists Midyear Meeting, December 2004. Orlando, Florida. **Wong SF**. (Poster Presentation)
22. "Cost-Effectiveness Analysis of the Selected First-Line Treatment Combinations of Fluorouracil, Leucovorin, Irinotecan, Oxaliplatin, and Bevacizumab in Metastatic colorectal Cancer". 1st Annual Meeting Hematology Oncology Pharmacy Association, June 2005, San Diego, California. Dzhangiryan K and **Wong SF**. (Poster Presentation)
23. "A Pilot Study to Evaluate the Efficacy and Safety of Palonosetron (Aloxi™) in Combination with Multiple-Day Dosing of Corticosteroid for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in a Community Oncology Practice." 1st Annual Meeting Hematology Oncology Pharmacy Association, June 2005, San Diego, California. **Wong SF**, Ugai J, and Quist R. (Poster presentation)
24. "Cost-effective Analysis of Palonosetron in Combination with 3-day corticosteroids for the Prevention of Chemotherapy-Induced Nausea and Nausea in a Private Practice Office". American College of Clinical Pharmacy 2005 Fall Annual Meeting, San Francisco, California. **Wong SF**, Ugai J, and Quist R. (Platform Presentation)
25. "Implementing a Tobacco Cessation Training Program for Healthcare Professionals in a Community Hospital Setting." 2nd Annual Meeting Hematology Oncology Pharmacy Association, June 2006, Orlando, Florida. Chen T, Matten P, Rutledge D, Quist R, Chung E, & **Wong SF**. (Poster Presentation- Oncology Fellow Best Poster Award)
26. "Effectiveness of Examination Blueprints to Promote Higher Cognitive Level Performance." American Association of Colleges of Pharmacy 2006 Annual Meeting and Seminars, San Diego, California. **Wong SF**, Quist R, and Murray W. (Poster Presentation)
27. "Implementing a Tobacco Cessation Training Program for Healthcare Professional in a Community Hospital Setting "American College of Clinical Pharmacy 2006 Fall Annual Meeting, St Louis, Missouri. Chen T, Matten P, Rutledge D, Quist R, Chung E, and **Wong SF**. (Encore Poster Presentation)
28. "A Pilot Study to Assess the Long Term Effectiveness of a Community Based Smoking/Tobacco Cessation Training Program for Healthcare Practitioners: A 3-Month Interim Analysis." . American College of Clinical Pharmacy 2006 Fall Annual Meeting, St Louis, Missouri. Chen T, Matten P, Rutledge D, Chung E, and **Wong SF**. (Platform Presentation)
29. "Implementation of a Pharmacist-Directed Research and Clinical Program at a Medical Oncology Private Practice Office. " American College of Clinical Pharmacy 2006 Fall Annual Meeting, St Louis, Missouri. **Wong SF**. (Poster Presentation)
30. "Evaluation of a Hospital Staff Training Program Focused on Smoking Cessation for Patients" Oncology Nursing Society 2007 9th National Conference on Cancer Nursing Research, Hollywood, California. Rutledge D, Matten P, Chen T, Quist R, Chung E, and **Wong SF**. (Poster Presentation)
31. "A Pilot Cross-over Study to Evaluate the Use of Regenecare™ Topical Gel in Patients with Cutaneous Toxicity caused by Epidermal Growth Factor Receptor (HER1/EGFR) Inhibitors" Oncology Nursing Society 2007 9th National Conference on Cancer Nursing Research, Hollywood, California. **Wong SF**, Lloyd K, Chen T, Vasko C, Mummaneni M and Osann K. (Poster Presentation)
32. "Implementing a Tobacco Cessation Training Program for Staff Nurses in a Community Hospital Setting" Oncology Nurse Society 32nd Congress Meeting, April 2007, Las Vegas, NV. Matten P, Chung E, Rutledge D, & **Wong SF** (Platform Presentation)
33. "Managing the Patient at Risk for Lung Cancer Through CT Lung Screening in a Community Hospital Setting" Oncology Nurse Society 32nd Congress Meeting, April 2007, Las Vegas, NV. Matten P, Fischel, R, Vu, D, & **Wong SF** (Platform Presentation)

34. "Implementation of a Pharmacist-Directed Research and Clinical Program at a Medical Oncology Private Practice Office." 3rd Annual Meeting of the Hematology Oncology Pharmacy Association (HOPA) June 2007. **Wong SF.** (Encore Poster Presentation)
35. "A Pilot Cross-over Study to Evaluate the Use of Regenecare™ Topical Gel in Patients with Cutaneous Toxicity caused by Epidermal Growth Factor Receptor (HER1/EGFR) Inhibitors- an Interim Analysis" 3rd Annual Meeting of the Hematology Oncology Pharmacy Association (HOPA) June 2007 **Wong SF**, Lloyd K, Vasko C, Mummaneni M and Osann K. (Encore Poster Presentation)
36. "Retrospective evaluation of the appropriate utilization of darbepoetin alfa and epoetin alfa in cancer patients with anemia." American College of Clinical Pharmacy (ACCP) Annual Meeting (October 14–17, 2007) in Denver, CO. Lin J, Quist R, Brown M, Sarakain R and **Wong SF.** (Poster Presentation)
37. "A Novel Model for Community Pharmacy Practice Residency to Promote Medication Therapy Management." CSHP Seminar October, 2007 in Palm Spring, California. CAPSLEAD TEAM - Khosho A, Umenoto H, Yang S, Mai K, Kaw L, Gupta E, Hess K, Shimomura S, and **Wong SF.** (Poster Presentation)
38. Berenson JR, Yellin O, Boccia RV, Flam MS, Wong S-F, Batuman O, Moezi MM, Woytowitz D, Duvivier H, Nassir Y, Swift RA, "Zoledronic Acid (ZOL) Markedly Improves Bone Mineral Density (BMD) for Patients (Pts) with Monoclonal Gammopathy of Undetermined Significance (MGUS) and Bone Loss," 2007 American Society of Hematology (ASH) Meeting December 2007 (Poster Presentation)
39. "A Novel Model for Community Pharmacy Practice Residency to Promote Medication Therapy Management." 42nd ASHP Midyear Clinical Meeting December 2-6, 2007 in Las Vegas, NV. CAPSLEAD TEAM - Khosho A, Umenoto H, Yang S, Mai K, Kaw L, Gupta E, Hess K, Shimomura S, and Wong SF. (Poster Presentation SP-334)
40. "A Novel Model for Community Pharmacy Practice Residency to Promote Medication Therapy Management." The California Pharmacists Association Annual Meeting Outlook 2008, February 7-10, 2008 in Sacramento, California. .CAPSLEAD TEAM - Khosho A, Umenoto H, Yang S, Mai K, Kaw L, Gupta E, Hess K, Shimomura S, and **Wong SF.** (Poster Presentation)
41. Berenson JR, Yellin O, Boccia RV, Flam M, **Wong S-F**, Batuman O, Moezi MM, Woytowitz D, Duvivier H, Nassir Y and Swift RA "Zoledronic Acid Markedly Improves Bone Mineral Density for Patients with Monoclonal Gammopathy of Undetermined Significance and Bone Loss," American Society of Clinical Oncology Annual Meeting June 2008, Chicago, IL. (Poster Presentation)
42. "Retrospective evaluation of the appropriate utilization of darbepoetin alfa and epoetin alfa in cancer patients with anemia." HOPA/ISOPP 2008 Conference (June 18th to 21st 2008) in Anaheim, California, USA. Lin J, Quist R, Brown M, Sarakain R and **Wong SF.** (Poster Presentation TR76)
43. "Evaluation of the Effectiveness of Panitumumab in Patients Who Were Treated and Failed Cetuximab". HOPA/ISOPP 2008 Conference (June 18th to 21st 2008) in Anaheim, California, USA. Hoang V, Purdy T, **Wong SF.** (Trainee Poster Presentation TR31)
44. "Case Report: An Evaluation of a Desensitization Protocol for Oxaliplatin-Induced Hypersensitivity Reactions." HOPA/ISOPP 2008 Conference (June 18th to 21st 2008) in Anaheim, California, USA. Oberbeck V and **Wong SF.** (Trainee Poster Presentation TR55)
45. "The Impact of the New Centers of Medicare & Medicaid Services (CMS) Guideline on the Efficacy, Safety, and Resources Utilization of Erythropoiesis Stimulating Agents (ESAs) in the Treatment of Chemotherapy-Induced Anemia." HOPA/ISOPP 2008 Conference (June 18th to 21st 2008) in Anaheim, California, USA. Green V, Bach T and **Wong SF.** (Trainee Poster Presentation TR77)
46. "Pilot cross-over study to evaluate Regenecare topical gel in patients with epidermal growth factor receptor (HER1/EGFR) inhibitors-induced skin toxicity. The Final Analysis". HOPA/ISOPP 2008 Conference (June 18th to 21st 2008) in Anaheim, California, USA. **Wong SF**, Osann K, Lloyd K, Lindgren A, Vasko K, Arenos R, Byun T, Mummaneni M. (Encore Poster Presentation EN1)
47. "A Cost-benefit analysis of a novel oncology pharmacy practice model in a private medical oncology office". HOPA/ISOPP (Hematology Oncology Pharmacy Association/International Society of Pharmacy Practice) 2008 Conference (June 18th to 21st 2008) in Anaheim, California, USA. **Wong SF.** (Poster number PR8)
48. "An Interprofessional Approach to Pharmacy Education". American Association of College of Pharmacy (AACP) 2008 Annual Meeting and Seminars (July 19-23, 2008) at Chicago, Illinois. **Wong SF**, Campbell A, Chung E, Aston S, Murray W, & Robinson D. (School Poster T80)
49. "A Cost-benefit analysis of a novel oncology pharmacy practice model in a private medical oncology office". American College of Clinical Pharmacy (ACCP) Annual Meeting (October 19-22, 2008) in Louisville, KY. **Wong SF.** (Encore Poster Presentation #239E)

- http://www.clinicaloncology.com/ViewArticle.aspx?d_id=151&a_id=12397
50. "The Clinical Quality Improvement (CQI) Process on the Use of Erythropoiesis Stimulating Agents (ESAs) Following the Updated Guideline of the Centers of Medicare & Medicaid Services (CMS) Started July 2007." American College of Clinical Pharmacy (ACCP) Annual Meeting (October 19-22, 2008) in Louisville, KY. Bach T, Green V, **Wong SF**. (Poster Presentation #237)
 51. "Spontaneous Regression of Erlotinib-Induced Papulopustular Rash: Need for New Management Approach?" Hematology Oncology Pharmacy Association HOPA 2010 Annual Meeting Nguyen H and **Wong SF**. (Poster Presentation)
 52. "Utilization of Evidence-Based Assessment to Develop Warfarin Protocol for Management of Venous Thromboembolism in Oncology Patients at an Oncology Medical Office". Hematology Oncology Pharmacy Association HOPA 2010 Annual Meeting. Liang C and **Wong SF**. (Poster Presentation)
 53. "Cost-Benefit Analysis of a Darbepoetin alfa Administration Order Form at a Private Oncology Practice." Annual Meeting of the Hematology Oncology Pharmacy Association (HOPA) March 2010. Yang S, Green V, Bach T, **Wong SF**. (Poster Presentation)
http://issuu.com/theoncologypharmacist/docs/2010_june
 54. "Evaluating the Effectiveness of a Question-Based Learning Method to Promote a Student-Centered Learning Paradigm" AACP (American Association of College of Pharmacy) Annual Meeting and Seminars, Seattle, WA July 10-13, 2010. Nguyen HM, **Wong SF**, Chung E, Pham DQ, & Law A. (Poster Presentation)
 55. "Outcome Evaluation of Interprofessional Education Using Objective Structural Clinical Examination (OSCE) as an Assessment Tool" AACP (American Association of College of Pharmacy) Annual Meeting and Seminars, Seattle, WA July 10-13, 2010. Pham DQ, **Wong SF**, Vats V, Campbell A, Chung E, Schwartzman E, & Hata M. (Poster Presentation)
 56. "Advancing Application of Therapeutic Knowledge and Skills by Implementing Integration Courses Throughout the Curriculum" AACP (American Association of College of Pharmacy) Annual Meeting and Seminars, Seattle, WA July 10-13, 2010. Chung E, Hoffman J, Scott J, **Wong SF** and Murray W. (School Poster Presentation)
 57. "Retrospective Evaluation to Examine Efficacy and Safety of Half-dose Pegfilgrastim in Breast Cancer Patients Receiving Cytotoxic Chemotherapy". 2010 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium, Washington DC October 1-3, 2010. Green V, Bounthavong M, Margelith D, **Wong SF**. (Abstract #116, Poster Presentation)
 58. "A Cross-Sectional Study to Evaluate Knowledge and Attitude Regarding Safe Handling of Oral Chemotherapy Among Health care Professionals, Patients, and Caregivers." 2012 Hematology Oncology Pharmacy Association (HOPA) Annual Meeting, Orlando, FL March 21-24, 2012. Nguyen C, Hernandez E, Spencer-Safier M, **Wong SF**. (Trainee Poster Presentation)
 59. "SWOG S0715: Randomized Placebo-Controlled Trial of Acetyl-L-Carnitine for the Prevention of Taxane-induced Neuropathy During Adjuvant Breast Cancer Therapy" (Abstract # 9018) 2012 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL. Hershman D, Unger, J, Crew K, Moinpour C, Minasian L, Hansen L, Lew D, Okane P, Wade JL, **Wong, SF**, Hortobagyi G, Meysken F, Albain K. (Poster Presentation S102)
 60. "Outcome Assessment of an Oral Chemotherapy Management Clinic: A 3-Month Report" (Abstract A-445-0005-00805) MASCC/ISOO 2012 International Symposium on Supportive Care in Cancer, New York, NY June 28-30, 2012. **Wong SF**, Nguyen C, Hernandez E. (Poster Presentation)
 61. "A cross-sectional, multidisciplinary study to evaluate knowledge and attitude of safe handling of oral chemotherapy" (Abstract A-445-0005-00828) MASCC/ISOO 2012 International Symposium on Supportive Care in Cancer, New York, NY June 28-30, 2012. Nguyen C, Hernandez E, **Wong SF**. (Poster Presentation)
 62. "Early Diagnostic Value of Survivin and its Alternative Splice Variants in Breast Cancers" 2012 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium September 13-15, 2012 San Francisco, CA.. Khan S, Yuan Y, Valenzuela M, Turay D, Ferguson H, **Wong SF**, Perez M, Mirshahidi S, Wall N (Poster Presentation C20)
 63. "Outcome Assessment of an Oral Chemotherapy Management Clinic: A Preliminary Report." 2012 American Society of Clinical Oncology (ASCO) Quality Care Symposium November 30-December 1, 2012, San Diego, CA. **Wong SF**, Nguyen C, Bounthavong M, Bechtoldt, K, Hernandez E. (Poster Presentation -Abstract #105)

64. "Outcome Assessments and Cost Avoidance of a Comprehensive Oral Chemotherapy Management Clinic" Hematology Oncology Pharmacy Association (HOPA) Annual Meeting March 2015. Austin, Tx. **Wong SF**, Bounthavong M, Nguyen C, Chen T. (Poster Presentation – Abstract PM14)
<http://www.pharmacist.com/pharma-industry-must-pay-drug-take-back-programs-some-california-counties>
65. "Interprofessional Education: Combining Nursing and Pharmacy" National Organization of Nurse Practitioner Faculties Annual Meeting April 22-26 2015. Baltimore, MD. Orfield J, Hanisch T, Alvarez, N, **Wong SF**. (Platform Presentation).
66. "Using ExamSoft™ and Examination Blueprints to Guide Development of Every 3-week Integrated Computerized Examination Question Pool" ExamSoft Assessment Conference June 3-4 2015, Lexington KY. **Wong SF**, Yamaki J, Tomaszewski, D. (Platform Presentation)
67. "Flipping Pharmacy Education: Supporting Faculty Through the Transition to a Learning-Centered Environment". AACP & AFPC Annual Meeting July 11-15, 2015, National Harbor, MD. Kammer R, Honeycutt, B, Yamaki, J, **Wong SF**. (Poster Presentation #30)
68. "Utilization of RxOutcome™ to Develop Curricular Integration Content Mapping". AACP & AFPC Annual Meeting July 11-15, 2015, National Harbor, MD. **Wong SF**, Yamaki, J. (Poster Presentation #39)
69. "Feasibility of Using a Student-Reported Survey to Assess Flipped Learning Out-of-Class Preparation Time". AACP & AFPC Annual Meeting July 11-15, 2015, National Harbor, MD. Yamaki, J, **Wong SF**. (Poster Presentation #41)
70. "Multi-Dimensional Curriculum Mapping to Assess Programmatic Student Learning Outcomes". AACP & AFPC Annual Meeting July 11-15, 2015, National Harbor, MD. Yamaki, J, **Wong SF**. (Poster Presentation #42)

UNIVERSITY and HEALTHCARE SYSTEM SERVICE

University Service

Chapman University

2014- 2015	Task Force on Research Infrastructure
2014 – Present	Institutional Review Board (IRB)
2015 – Present	Student Evaluation Task Force

Brandman University

2014 – Present	Musco School of Nursing and Health Professions Advisory Board
----------------	---

Chapman University School of Pharmacy (CUSP)

2015 – Present	Item Review Committee - <i>ex officio</i>
2015 – Present	Assessment Committee – <i>ex officio</i>
2014 – Present	Academic Affairs Committee – <i>ex officio</i>
2014 – 2015	Faculty Review Council (FRC) - Chair
2014 – 2015	Pharmacy Practice Department Faculty Search Committee
2013 – 2014	Pharmacy Practice Department Faculty Search Committee – Interim Chair
2013 - 2014	Biomedical and Pharmaceutical Science Department Faculty Search Committee
2013 – 2014	Pharmacy Practice Department Chair Search Committee – Chair
2013 – 2014	Biomedical and Pharmaceutical Science Department Chair Search Committee

Loma Linda University Campus-Wide

2010 – 2013	Loma Linda University Clinical Trial Committee Center Oversight Committee
-------------	---

Loma Linda University School of Pharmacy

2012 – 2013	Assessment Committee - Member
-------------	-------------------------------

2010 – 2012	Assessment Committee - Chair
2010 – 2013	Continuing Professional Development Committee
2010 – 2012	Curriculum Committee – Liaison

Western University Campus-Wide

2009-2010	Inter-professional Education (IPE) Program College of Pharmacy Liaison
2009-2010	Inter-professional Education (IPE) Program Design Team
2007-2008	Inter-professional Education (IPE) Pilot Study Group
2003-2006	Western University Faculty Senate (elected member)
1998-2002	UCI Cancer Committee Chemotherapy Continuous Quality Improvement Subcommittee – Chair
1998–2001	Western University of Health Sciences Interdisciplinary Curriculum Committee Clinical Conference Planning Sub-committee
1997-2002	UCI Cancer Committee
1996-2002	UCI Chao Comprehensive Cancer Center Clinical Trials Protocol Review and Monitoring Committee
1994-2002	UCI Chao Comprehensive Cancer Center Clinical Cancer Center Clinical Research Office Committee

Western University College of Pharmacy

2009-2010	Interprofessional Education (IPE) COP Task Force – Chair (appointed)
2009-2010	Interprofessional Education (IPE) COP Pre-Clinical Group – Chair (appointed)
2007-2010	Fellowship and Residency Oversight Committee (appointed)
2008-2009	Bylaw Oversight Committee (appointed)
2007-2008	Promotion and Tenure Committee (elected)
2006	Pharmacy Practice Department ad hoc Comprehensive Exam Committee (appointed)
2006-2007	Ad Hoc Faculty Development and Critical Needs Assessment Committee (appointed)
2006-2007	Merged Promotion and Tenure Committee– Chair (elected)
2006-2008	Curriculum Committee (appointed)
2005-2006	Promotion and Tenure Committee Merger ad hoc Committee – Chair (appointed)
2005	Faculty Title and Rank Policy ad hoc Committee- Chair (appointed)
2005-2006	Policy Oversight Committee (elected)
2005-2007	Pharmacy Practice and Administration Department Chair Search Committee (appointed)
2005-2006	Pain Management Curriculum Focus Group -Chair (appointed)
2004-2006	ACPE Self-Study Subcommittee in Faculty Workload and Promotion -Chair (appointed)
2004-2006	ACPE Self-Study Subcommittee in Standards for Organization and Administration (appointed)
2003-2006	Non-tenure Faculty Promotion Committee (appointed)
2003-2006	Promotion and Tenure Committee -Chair for 2005-2006 (elected)
2002	Research and Graduate Programs Committee (appointed)
2002-2005	Pharmaceutical Sciences Faculty Search Committee (appointed)
2001-2002	Faculty Assembly-Chair) (elected)
2000-2002	Dean’s Council Faculty Representative (elected)
2001-2002	Advanced Elective Program Task Force –Chair (volunteered)
2001	Clinical Faculty Search Committee –Chair (appointed)
2000- 2001	Faculty Assembly -Vice-Chair (elected)
2000- 2001	ad hoc Pharmacy Practice Department Chair Search Committee –Chair (appointed)
2000-2001	Non-tenure Track Document ad hoc Sub-committee (appointed)
1999-2000	Clinical Faculty Search Committee (co-chair)
1999-2002	Practice Faculty Scholarship Committee
1998-2001	Promotion and Tenure Committee

1998-1999	Faculty Search Committee
1998-2001	Academic Performance and Standards Committee
1997-1998	Competency Ad Hoc Committee
1997-1998	Clinical Faculty Search Committee
1995-1996	University of California San Francisco, School of Pharmacy WOS Faculty Advisory Committee

Clinical Care Service

Inter-Departmental

2007-2009	St. Joseph Hospital Cancer Institute Cancer Research Committee
2005-2009	St. Joseph Hospital Smoking Cessation Education Program Consultant
2005-2009	St. Joseph Hospital Cancer Institute Prostate Cancer Group
2003-2009	St. Joseph Hospital Cancer Institute Melanoma Group
2003-2009	St. Joseph Hospital Cancer Institute Lung Cancer Group
1997-2002	UCIMC Melanoma Center Pharmacist Consultant
1997-2002	UCIMC Bone Marrow Transplantation Program Pharmacist Consultant
2000-2002	UCIMC MUPIT Committee
1995-1996	UCIMC Ovarian Cancer Carepath Committee
1995-1997	UCIMC Bone Marrow Transplantation Pharmacist Coordinator
1994-1996	UCIMC Chemotherapy Performance Improvement Task Force
1991-1992	UCIMC Clinical Cancer Center Steering Committee
1990-1992	UCIMC Clinical Cancer Center Annual Nursing Pharmacy Conference Planning Committee
1990-1991	UCIMC Pediatric Oncology Committee
1989-1990	UCIMC Clinical Cancer Center Ancillary Service Sub-committee
1989-1990	UCIMC Clinical Cancer Center Infusion Center Planning Committee

Departmental

1999-2000	UCIMC Pharmacy Residency Program Review Committee
1994-1997	UCIMC Safety on Site Coordinator - Cancer Center Chemotherapy Pharmacy
1990-1997	UCIMC Pharmacy Residency Program Review Committee
1990-1991	UCIMC Pharmacy Peer Review Committee
1990	UCIMC Pharmacist Reclassification Review Committee

RESEARCH & GRANTS

9/88	A Clinical Trial of Neoadjuvant Chemotherapy with Cisplatin, Continuous Infusional 5-FU and Etoposide Followed with Surgery and Radiation for Stage III & IV Head and Neck Cancer Division of Hematology/Oncology, UCIMC Co-investigator
1/89	Treatment of Advanced Primary Cervical Cancer Using Radiotherapy Combined with Bolus Cisplatin and Continuous 5-FU Infusion Division of Gynecology/Oncology, UCIMC Co-investigator
2/89	Cyclosporin A (CsA) Enhancement of Conventional Chemotherapy in Lung Cancer Division of Hematology/Oncology, UCIMC Co-investigator Sponsor: Sandoz
6/90	Evaluation of Activity of Floxuridine + Etoposide + Cisplatin in Refractory Carcinomas Division of Hematology/Oncology, UCIMC

Co-Principal Investigator

- 1/91 Safety and Efficacy of Pimozide plus Verapamil Combined with Continuous Infusion Fluorouracil in Refractory Colorectal Cancer (Principal Investigator Initiated Trial)
Division of Hematology /Oncology, UCIMC
Co-investigator
- 3/91 A Randomized Double-Blind Comparison of Oral Ondansetron and Compazine Spansules in the Prevention of Nausea and Vomiting Associated with Non-cisplatin Chemotherapy
Division of Hematology/Oncology, UCIMC
UCIMC Co-investigator Sponsor – Glaxo
- 5/91 Phase II Trial of Doxorubicin and Ifosfamide with Mesna in the Treatment of Metastatic Breast Cancer (Principal Investigator Initiated Trial)
Division of Hematology/Oncology, UCIMC
Atiba J, Armentrout S, **Wong SF** (co-investigator)
- 5/91 A Phase IV, Open Label Multicenter Study of Neupogen as an Adjunct to Myelosuppression Chemotherapy in Cancer Patients
Division of Hematology/Oncology, UCIMC
Atiba J, **Wong SF** (site Co-investigator)
Sponsor - Amgen
- 6/92 Modulation of Cytotoxic Chemotherapeutic Agents and Potential Pharmacokinetic Interactions: Interferon & 5-Fluorouracil Interaction Studies (Principal Investigator Initiated Trial)
Division of Hematology/Oncology, UCIMC
Wong SF, Atiba J, Armentrout S
- 1/93 A Phase III Trial of Chronic Infusional 5-Fluorouracil (5-FU) and Alpha Interferon (IFN) in Advanced Colorectal Carcinoma (Principal Investigator Initiated Trial)
Division of Hematology/Oncology, UCIMC
Armentrout S and **Wong SF**
Sponsor: Schering (\$20,000)
- 2/93 A Multicenter Phase II Study of all Trans-Retinoic Acid and Interferon-2a in Drug Resistant Multiple Myeloma and Waldenstrom's Macroglobulinemia
Division of Hematology/Oncology, UCIMC
Pharmacist Coordinator
Sponsor: National Cancer Institute
- 10/93 Liposomal Doxorubicin in Recurrent Breast Cancer
Division of Hematology/Oncology, UCIMC
Atiba J and **Wong SF**
UCIMC Co-investigator
Sponsor: Pfizer Pharmaceuticals
- 6/94 Laser Therapy for Oral Mucositis in Patients Receiving Chemotherapy (Principal Investigator Initiated Trial)
Division of Hematology/Oncology, UCIMC
Wilder-Smith P, **Wong SF** (co-PI), Anderson J, Makalino A
Sponsor: Beckman Laser Institute (\$72,000)
- 1/95 Phase II Trial of Taxol and Carboplatium in Head and Neck Cancer (Principal Investigator Initiated Trial)
Division of Hematology/Oncology, UCIMC
Ku N and **Wong SF** (co-investigator)
Sponsor: Bristol Myers Oncology

- 1/95 A Cost Comparison Study of Oral vs. Intravenous Antiemetic Regimens in the Prevention of Nausea and Vomiting Associated with Antineoplastic Chemotherapy (Mild to Moderate Emetogenic Potential) (Principal Investigator Initiated Trial)
Department of Pharmaceutical Services & Division of Hematology/Oncology, UCIMC
Wong SF (PI)
- 4/95 "Proper Handling of Research Drugs" Instructional video for Southwest Oncology Group Research Member Institutions and Affiliates. - Southwest Oncology Research Group
Project Coordinator and Technical Consultant
Sponsor: Bristol-Myers Oncology and Southwest Oncology Group (\$20,000)
- 3/96 Evaluation of the Cost-Effectiveness of Replacing IV Ondansetron with Oral Granisetron in Cisplatin- or Carboplatin-based Chemotherapy (Principal Investigator Initiated Trial)
Department of Pharmaceutical Services, UCIMC
Wong SF (PI)
- 3/97 Phase II Trial of Taxol and Cyclosporin in Advanced Non-Small Cell Lung Cancer (Principal Investigator Initiated Trial)
Division of Hematology/Oncology, UCIMC
Veteran Administration Hospital of Long Beach
Slater L, Ross H, **Wong SF** (co-investigator)
Sponsor: National Cancer Institute
- 12/97 Pharmacoeconomics Analysis of Oral Kytril vs Intravenous Ondansetron in Patients Receiving Conditioning Regimens for Blood or Marrow Transplantation
Western U of Health Sciences and University of California, Irvine Medical Center Chao Family Comprehensive Cancer Center
Wong SF (PI), Chau HV, Keuroghelian S, Lim S, and Ho W.
- 10/98 CAPSS-078 Multi-center Randomized Study to Compare the Safety and Efficacy of Oral Levofloxacin vs. Parenteral Ceftriaxone and Amikacin with the Potential of Conversion to Oral Ciprofloxacin and Amoxicillin/Clavulanate in the Treatment of Subjects with Talcott Group IV Febrile Neutropenic
Division of Hematology/Oncology, University of California, Irvine
Wong SF and Lim S (co-PI)
Sponsor: Ortho-McNeil (\$70,000)
- 11/98 Evaluation of Diagnosis and Treatment of Depression in the Breast Cancer Patients (Principal Investigator Initiated Trial)
Western U of Health Sciences and University of California, Irvine Medical Center
Franson K, **Wong SF**
Sponsor: Western U of Health Sciences (\$2,000)
- 2/99 Pilot Study to Evaluate Mirtazapine in the Management of Depression Associated with Chronic Interferon Therapy in the Melanoma Patients (Principal Investigator Initiated Trial)
Division of Hematology/Oncology & Surgical Oncology, UCIMC
Wong, SF, Franson K, Jakowatz J, & Linden K
Sponsor: Schering-Plough (\$40,000)
- 04/00 Sunbelt Melanoma Trial (SMT): A Multicenter Trial of Adjuvant Interferon Alfa-2b for Melanoma Patients with Early Lymph Node Metastasis Detected by Lymphatic Mapping and Sentinel Lymph Node Biopsy
Division of Surgical Oncology, UCIMC
UCIMC Co-Investigator
Sponsor: Schering-Plough (\$60,000)

- 07/00 A Prospective, Randomized, Open-Label, Comparative Clinical Trial in Post-Surgical Melanoma Patients with Either DNP-Modified Autologous Tumor Vaccine or Interferon Alpha-2b
Division of Surgical Oncology, UCIMC
UCIMC Co-Investigator
Sponsor: AVAX Technologies, Inc (\$142,739)
- 9/00 A Phase I Dose-Ranging Safety Study Using Intranodal Delivery of a Plasmid DNA (Synchrotope TA2M) in Adult Stage IV Melanoma Patients
Division of Surgical Oncology, UCIMC
UCIMC Co-Investigator
Sponsor: CTL Immunotherapeutics, Inc (\$50,000)
- 11/00 Open Label Study of ONTAK[®] (denileukin diftitox, DAB³⁸⁹ IL-2) to Estimate Response in Cutaneous T-Cell Lymphoma (CTCL) according to CD25 Status (Principal Investigator Initiated Trial)
Francine F, Duvic M, Cooper P, and **Wong SF** (co-investigator)
Sponsor: Ligand Pharmaceutical Inc. (\$700,000)
- 2/01 Laser Therapy for the Management of Mucositis in Head and Neck Cancer Patients Receiving Radiation Therapy ± Chemotherapy (Principal Investigator Initiated Trial)
Beckman Laser Institute, UCI & University of California, Irvine Medical Center Chao Family Comprehensive Cancer Center
Wilder-Smith P, **Wong SF** (co-PI), Kuo J, and Ramsingahi N
Sponsor: *Susan Samueli Center for Complementary and Alternative Medicine (submitted for funding \$96,899, not funded)*
- 6/01 A Retrospective Single Center Study Comparing the Efficacy, Tolerability, and Pharmacoeconomics of Granulocyte Colony stimulating Factor (G-CSF) and Macrophage Granulocyte Colony Stimulating Factor (GM-CSF).
University of California, Irvine Medical Center
Chan H, Okomoto M, Knapp K, and **Wong SF** (Residency major project mentor)
- 2/02 Loss of Alemtuzumab Due to Binding to Plastics (Principal Investigator Initiated Trial)
Western University of Health Sciences, College of Pharmacy
Lambros M and **Wong SF** (co-PI)
Sponsor: Berlex Laboratory (\$19,000-did not execute)
- 4/02 Clinical Outcomes in Patients with HER2 Gene-amplified Metastatic Breast Cancer Treated with First-Line Herceptin[®] in Combination with a Taxane: A Phase IV, Prospective Community-Based Study
Hematology Oncology Medical Group of Orange County
Mummaneni M and **Wong SF** (site co-PI)
Sponsor: Genentech Inc. (\$40,000)
- 6/02 A Randomized, Open Label, Multicenter Study of Primary Prophylaxis with Neulasta[®] (Pegfilgrastim) Versus Secondary Prophylaxis as an Adjunct to Chemotherapy in Elderly Subjects (≥ 65 y.o.) with Cancer
Hematology Oncology Medical Group of Orange County
Armentrout S and **Wong SF** (site co-PI)
Sponsor: Amgen Inc. (\$40,000)
- 10/02 Prospective Surveillance of Delayed Nausea and Vomiting in Cancer Patients in a Community-Based Oncology Practice (Principal Investigator Initiated Trial)
Western University of Health Sciences, College of Pharmacy
Wong SF
Sponsor: Medical School Substance P Grant by Merck & Co., Inc (\$30,000)

- 08/03 Protocol H3E-US-JMFE (b) Open Label Study of ALIMTA (pemetrexed) alone or in Combination with Cisplatin for Patients with Malignant Mesothelioma (Patient Access Program)
Hematology Oncology Medical Group of Orange County
Lindgren T, **Wong SF** (co-PI)
Sponsor: Eli Lilly
- 08/03 Evaluation of *in vitro* Chemosensitivity-Directed Assay Test in the Treatment of Advanced Stages (IIIA, IIIB, and IV) of Non-Small Cell Lung Cancer (Principal Investigator Initiated Trial)
Hematology Oncology Medical Group of Orange County
Wong SF, Lindgren T, Kern D, Palafox B, Ott R, Fischel R, and Liao SY
- 10/03 Breast Cancer Siblings Database Study
Wong SF (site coordinator)
Sponsor: GenBasix, Inc
- 12/03 A Prospectively Randomized, Phase III, Multicenter, Controlled Trial to Evaluate the Safety and Efficacy of the Zevalin® Therapeutic Regimen Plus Rituxan® Compared With Rituxan Alone in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma
Investigators: Winston Ho and **Wong SF** (site co-PI)
Sponsor: IDEC Pharmaceuticals Corp (\$108,500 - \$133,500)
- 12/03 Pharmacokinetic Assessment of Every 2-week epoetin alfa (Procrit®) in Patients with Non-myeloid Malignancies (Principal Investigator Initiated Trial)
Western University of Health Sciences, College of Pharmacy
Wong SF and Lambros M
Sponsor: Ortho Biotech, L.P.(\$100,000 + drug supply of \$585,000 per AWP price)
- 12/03 FluCam 106: Phase II Trial Comparing Combination Treatment with Fludarabine and Alemtuzumab to Fludarabine and Rituximab in Patients with B-Cell Chronic Lymphocytic Leukemia Requiring Treatment After 1st Line Therapy
Ho W, **Wong SF**, et al (co-investigator)
Sponsor: Berlex Laboratories (\$25,000)
- 03/04 MAC-001: A Prospective, Open-Label, Safety and Efficacy Study of Combination Treatment with Melphalan, Arsenic Trioxide and Ascorbic Acid in Patients with Relapsed or Refractory Multiple Myeloma. Protocol 001
Lindgren T, **Wong SF** (co-Principal Investigators)
Sponsor: Oncotherapeutics, Inc (\$20,000)
- 06/04 FIRST study” A Multi-center, Open-Label, Phase IV Study of Pegfilgrastim administered in the First and Subsequent Cycles of Myelosuppressive Chemotherapy.
Lindgren T, **Wong SF**, et al (co-investigator)
Sponsor: Amgen Oncology (\$40,000)
- 06/04 ZOMGUS-001: a Phase I/II Trial of Zometa in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS).
Lindgren T, **Wong SF** (co-Principal Investigators)
Sponsor: Oncotherapeutics, Inc (\$20,000)
- 04/05 ZOMETA® Z-MAX Protocol No. CZOL446EUS97: A Multicenter, Open-Label, Randomized Trial evaluating the Duration of Infusion of ZOMETA (zoledronic acid) 4 mg IV in Multiple Myeloma Patients with Bone Metastasis
Ho, W, **Wong SF**, et al (co-investigator)
Sponsor: Novartis (\$30,000)

- 05/05 The CAFÉ study: Cancer Patient Fracture Evaluation. A Multicenter, Prospective, Randomized Controlled Study to Compare Balloon Kyphoplasty to Non-Surgical Fracture Management in the Treatment of Painful, Acute Vertebral Body Compression Fractures in Cancer Patients.
Lindgren T, Carlson C, **Wong SF**, et al. (co-investigator)
Sponsor: Kyphon Inc (\$60,000)
- 05/05 AMGEN 20040249 PACCE Study: A Randomized, Open-label, Controlled, Clinical Trial of Chemotherapy and Bevacizumab With and Without Panitumumab in the First-line treatment of Subjects with Metastatic Colorectal Cancer.
Byun T, **Wong SF**, et al (co-investigator)
Sponsor: Amgen (\$70,000)
- 06/05 Validity Evaluation on the Calculating Creatinine Clearance (policy Memorandum No. 38) on Carboplatin Dosing and its Impact on Drug Toxicity. (Principal Investigator Initiated Trial)
Southwest Oncology Group Pharmacy Committee
Committee member Investigators: **Wong SF** and Chan H (Principal Investigator)
Consulting Investigator: Quist R
Sponsor: Southwest Oncology Group
- 01/06 PIX 203 Study: Cyclophosphamide, Doxorubicin, Vincristine, Prednisone plus Rituximab (CHOP-R) and Cyclophosphamide, Pixantrone, Vincristine, Prednisone plus Rituximab (CPOP-R) in Elderly Patients with Diffuse Large-B-cell Lymphoma: A Phase II, Randomized, Multicenter, Comparative Trial.
Wong SF and Ho W (co-Principal Investigator)
Sponsor: CTI (\$60,000)
- 03/06 A Pilot Cross-Over Study to Evaluate the Use of Regenecare™ Topical Gel in Patients with Cutaneous Toxicity Caused by Epidermal Growth Factor Receptor (HER1/EGFR) Inhibitors. (Principal Investigator Initiated Trial)
Wong SF, Chen T, Mummaneni M, and Quist R (Principal Investigator)
Sponsor: MPM Medical Inc. (\$10,000 + drug supply)
- 04/06 A Phase II Trial of Bortezomib + Ascorbic Acid + Melphalan (BAM) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma
Lindgren T, & **Wong SF** (co-Principal Investigator)
Sponsor: Oncotherapeutics (\$17,500)
- 05/06 ATLAS (Randomized, Double-Blind Placebo-Controlled, Phase IIIb Trial Comparing Bevacizumab Therapy with or without Erlotinib After Completion of Chemotherapy with Bevacizumab for the First-Line Treatment of Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Wong SF (Principal Investigator)
Sponsor: Genentech (\$350,000)
- 07/06 A Phase I/II Trial of ZIO-101 in Advanced Multiple Myeloma
Lindgren T & **Wong SF** (co-Principal Investigator)
Sponsor: Ziopharm Oncology (\$78,985)
- 07/06 Phase II Trial of Neoadjuvant Chemotherapy for the Treatment of IA-IIIa Non-Small Cell Lung Cancer (Principal Investigator Initiated Trial)
Wong SF (Principal Investigator)
- 11/06 Psychosocial Interventions +/- Pharmacotherapy to Manage Cancer Depression ((Principal Investigator Initiated Trial)
Wong SF (Principal Investigator)

- Sponsor: American Cancer Society Pilot and Exploratory Projects in Cancer Control and Prevention Research RFA Palliative Care (\$139,000 Not funded; Score = satisfactory)
- 01/07 A Randomized Phase II Trial of ATN-224 in Combination with Temozolomide or Temozolomide Followed by ATN-224 in Patients with Advanced Melanoma.
Lindgren T and **Wong SF** (site co-Principal Investigator)
Sponsor: Attenuon, LLC (\$34,980)
- 02/07 Assessment of Community Based Smoking/tobacco Cessation Training Program for Healthcare professionals (Principal Investigator Initiated Trial)
Matten P, **Wong SF**, Rutledge D, & Chung E
- 06/07 Comparative Assessment of ERCC1 Expression in Lung and Colon Cancer Patients (Principal Investigator Initiated Trial)
Wong SF and Huang Y (co-Principal Investigator)
Sponsor: Western University Intramural Grant (\$20,000)
- 07/07 Individualizing DNA Repair Profiles to Improve Platinum-Based Chemotherapy (Principal Investigator Initiated Trial)
Wong SF (Principal Investigator)
American College of Clinical Pharmacy Frontier Grant (\$29,940) – not funded
- 08/07 GSK 109493: A Double-blind, Randomized, Placebo-controlled Phase III Study to Assess the Efficacy of recMAGE-A3 + AS15 Antigen Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients with Resectable MAGE-A3-Positive Non-Small Cell Lung Cancer,
Byun, T, **Wong SF**, et al (Sub-Investigator)
Sponsor: GlaxoSmithKline
- 08/07 Genentech AVF3991n: An Observational Study of Avastin (Bevacizumab) in Combination with Chemotherapy for Treatment of Metastatic or Locally Advanced and Unresectable Colorectal Cancer, Locally Advanced or Metastatic Non-Small Cell Lung (Excluding Predominant Squamous Cell Histology), or Locally Recurrent or Metastatic Breast Cancer.
Wong SF, et al (Site Principal Investigator)
Sponsor: Genentech (\$50,000)
- 08/07 Genentech OSI3926g: Pilot Study of Changes in FDG- and FLT-PET Imaging in Patients with Non-Small Cell Lung Cancer Following Treatment with Erlotinib.
Byun T, **Wong SF** (Sub-Investigator)
Sponsor: Genentech (\$32,347)
- 04/09 A Retrospective Study to Evaluate Bone Loss and Disease in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS)
Wong SF (Site Principal Investigator)
Sponsor: ONCOtherapeutics (\$6,800)
- 12/09 Retrospective Comparative Evaluation of Epidermal Growth Factor Receptor Inhibitors-induced dermatologic toxicities between Japan and United States: Is there a Difference?
Wong SF, Protocol Chair and Principal Investigator (USA), Etsuko UEJIMA, PhD, Principal Investigator (Osaka University, Japan)
USA Investigators:
Loma Linda University: Hamid Mirshahidi, MD, Jefmar Dickey, PY4; Erica Yunson Lee, PY3.
Memorial Sloan Kettering Cancer Center: Mario Lacouture, MD; Nelly G. Adel, PharmD, BCOP, BCPS
VA San Diego Medical Center: Timothy Chen, PharmD; Muoi Gi, PharmD; Mark Bounthavong, PharmD

- Osaka University, Japan Investigators:** Sari Nakagawa, M. Pharm, Yoshiaki Okamoto, B. Pharm, Takashi Tagawa, B. Pharm, Takako Nozawa
- 4/05-12/08 Southwest Oncology Group Pharmaceutical Sciences Committee Grant
Reverse Site Visit Competitive Grant
Wong SF (Committee Chair – Grant application key personnel)
Sponsor: National Cancer Institute - The Regents of the University of Michigan (\$31,000/year)
- 4/10 S1013 A Phase II Prospective Study of Epidermal Growth Factor Receptor (Her-1/EGFR) Inhibitor-Induced Dermatologic Toxicity: Validation of the Functional Assessment of Cancer Therapy – EGFR18 (FACT-EGFR18) Questionnaire for EGFR1-induced skin toxicities.
Wong SF (Study Chairman), C Moinpour, J Wade, K Humpries, J Unger, M Lacouture, L Wagner,
Sponsor: Southwest Oncology Group/ Division of Cancer Prevention, NCI – *Activated 11/13/2011*
(\$430,000 – \$630,000)
- 6/10 S1009 A Pilot Randomized Double-Blinded Placebo-Controlled Study to Evaluate the Use of a Topical Wound Gel (Regenecare®HA Wound Care Gel) in Patients with Cutaneous Toxicity Caused by Epidermal Growth Factor Receptor (HER1/EGFR) Inhibitors
Wong SF (Study Chairman), C Moinpour, G Anderson, J Wade
Sponsor: Southwest Oncology Group
Grant submission to Division of Cancer Prevention at NCI – not funded (\$106,000)
- 9/10 Assessing the Inter-rater Reliability of a New Chart Note Grading Rubric
Nguyen L, Florea, N, Hernandez, E, **Wong SF**
Loma Linda University School of Pharmacy
- 1/11 A Randomized Double-Blinded Placebo-Controlled Study to Evaluate the Use of a Topical Wound Gel (Regenecare™HA Wound Care Gel) in Patients with Cutaneous Toxicity Caused by Epidermal Growth Factor Receptor (HER1/EGFR) Inhibitors
Wong SF, Mirshahidi H, Hsueh CT, Chen CS, Mirshahidi S, Osann L
Sponsor: Bristol Myers Squipps (\$215,815.86 -*Not funded*)
- 2/11 Prognostic Value of Survivin Alternative Splice Variants in Triple Negative Breast Cancers
Yuan Y, Wall N, **Wong SF** (sub-investigator), Morgan J, Chen CS
Sponsor: SWOG HOPE Foundation Grant (\$250,000-*Not funded*)
- 3/11 Outcome Assessment of a Multidisciplinary Focused-Care in Non-Small Cell Lung Cancer: A Retrospective Review
Wong SF, Mirashahidi H, Hernandez, E
Loma Linda University Cancer Center
- 10/11 A Cross-Sectional Study to Evaluate Knowledge and Attitude Regarding Safe Handling of Oral Chemotherapy Among Health care Professionals, Patients, and Caregivers.
Wong SF, Nguyen C, and Hernandez E
Loma Linda University Cancer Center
- 2/15 A Pragmatic Trial to Improve Colony Stimulating Factor Use in Cancer
PI: Scott Ramsey
Wong SF (Role: External Expert Advisor)
University of Washington Fred Hutchinson Cancer Research Center
Sponsor: PCORI – Patient-Centered Outcomes Research Institute (\$7.7M)
- 03/15 Chapman University School of Pharmacy (CUSP) Assessment Program Master Protocol.
PI: **Wong SF**
Chapman University School of Pharmacy

- 1/09 - SWOG Sub-awards:
 Present NCORP Research Base (0.9 calendar month) (\$26,282/year)
 NTCN SWOG Network Group Operation Center (1.8 calendar month) (\$47,347/year)
PI: Wong SF
 Sponsor: NIH/National Cancer Institute
- 08/15 “Formulation of Topical Vitamin K1 for Epidermal Growth Factor Receptor Inhibitors (EGFRIs)-Induced skin rash”.
 Co-PI: **Wong SF** and Montazeri, H
 Sponsor: HOPE Foundation SWOG Early Exploration and Development (SEED) Grant (\$60,338)

PUBLICATIONS

Journal Articles

Peer-reviewed

1. Atiba J, Meyskens FL Jr, Schell MJ, Armentrout SA, Cho J, **Wong SF**, et al. “All-trans Retinoic Acid: Preliminary Evidence for Efficacy in Recurrent High Grade Malignant Gliomas and Effect of Drug Holiday Versus Alpha Interferon Therapy on Restoration of tRA Bioavailability.” *Annals in Oncology* 1996;7:613p.
2. Ross HJ, Cho J, Osann K, **Wong SF**, Ramsinghani N, Williams J, et al “Phase I/II Trial of Low Dose Cyclosporin A with EP for Advanced Non-Small Cell Lung Cancer .” *Lung Cancer* 1997;Vol 18;189-198.
3. **Wong SF**. “Oral Bexarotene in the Treatment of Cutaneous T-Cell Lymphoma”. *Annals of Pharmacotherapy*. CE/Formulary Forum 2001; 35(9): 1056-1065.
4. **Wong SF** & Wilder-Smith P. “Pilot Study of Laser Effect on Oral Mucositis in Patients Receiving Chemotherapy” *The Cancer Journal* 2002; 8:247-254.
5. **Wong SF**, Lindgren T, Hsu D, & Tran G. “Low Dose Gemcitabine and Cisplatin in the Treatment of Refractory Non-Hodgkin’s Lymphoma.” (Letter to the Editor) *American Journal of Hematology* 2003 Aug;73(4):298.
6. **Wong SF**, Jakowatz J, & Taheri R. "Management of Hypertriglyceridemia in Patients Receiving Interferon for Malignant Melanoma". *The Annals of Pharmacotherapy*, 2004 October, Volume 38, pp. 1655-1659.
7. **Wong SF** & Chan H. “Formulary Change from Filgrastim (G-CSF) To Sargramostim (GM-CSF) in Patients Receiving Myelosuppressive Chemotherapy”. *Pharmacotherapy* 2005; 25(3):372-378.
8. **Wong SF**. “Cetuximab: An Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody for the Treatment of Colorectal Cancer”. *Clinical Therapeutics* 2005; 27(6): 684-694.
9. **Wong SF**, Jakowatz J, & Taheri R. “Potential Drug Interaction between Interferon and Gemfibrozil in a Malignant Melanoma Patient”. *Clinical Therapeutics* 2005; 27(12):1942-1948.
10. **Wong SF**. “Trastuzumab and Cardiotoxicity: Weighting the Risks” (Editorial) *American Journal of Health-System Pharmacy* 2006; 63:525
11. Berenson J, Boccia R, Siegel D, Bozdech M, Bessudo A, Stadtmauer E, Pomeroy JT, Steis, R, Flam, M, Lutzky J, Jilani S, Volk J, **Wong SF**, Moss R, Patel R, Ferretti D, Russell K, Louie R, Yeh H, and

- Swift R. "Efficacy and Safety of Melphalan, Arsenic Trioxide and Ascorbic Acid Combination Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Prospective, Multicentre, Phase II, Single Arm Study". *British Journal of Haematology* 2006; 135:174-183.
12. **Wong SF**. "Dasatinib Dosing Strategies in Philadelphia Chromosome-Positive Leukemia." *Journal of Oncology Pharmacy Practice* J Oncol Pharm Pract. 2009 Mar;15(1):17-27. Epub 2008 Aug 27. http://pharmacypracticenews.com/ViewArticle.aspx?d=Clinical&d_id=50&i=June%2B2009&i_id=532&a_id=13331
 13. Berenson JR, Yellin O, Boccia RV, Flam M, **Wong S-F**, Batuman O, Moezi MM, Woytowitz D, Duvivier H, Nassir Y and Swift RA, "Zoledronic Acid Markedly Improves Bone Mineral Density for Patients with Monoclonal Gammopathy of Undetermined Significance and Bone Loss," *Clinical Cancer Research* 2008 Oct 1;14(19):6289-95.
 14. **Wong SF**. "New dosing schedules of dasatinib for CML and adverse event management" *Journal of Hematology and Oncology* 2009 February;2:10
 15. **Wong SF** "Implementation of a Pharmacist-Directed Research and Clinical Program at a Medical Oncology Private Practice Office" *Journal of Oncology Practice* (Submitted)
 16. **Wong SF**, Lindgren A, Vasko C, Arenos R, Mummaneni M, Byun T, Alexson E, and Osann K "A Pilot Cross-over Study to Evaluate the Use of Regenecare™ Topical Gel in Patients with Cutaneous Toxicity caused by Epidermal Growth Factor Receptor (HER1/EGFR) Inhibitors" *Journal of Supportive Oncology* 2010 Sep-Oct;8(5):202-8.
 17. Bourdeanu L & **Wong SF** "Supporting Asian Patients with Metastatic Breast Cancer during Ixabepilone Therapy" *Expert Opinion and Drug Safety*. 2010 May;9(3):383-96. Epub 2010 Jan 28.
 18. Matten P, Rutledge D, Morrison V, Chen T, Chung EP, **Wong SF**. "Evaluation of Tobacco Cessation Classes Aimed at Hospital Staff Nurses" *Oncology Nursing Forum* 2011 January;38(1):67-73
 19. **Wong SF** & Mirshahidi H. "Management of Patients with CML: Practical Applications for Pharmacy Practitioners." *The Annals of Pharmacotherapy*. 2011 June; 45:787-797.
 20. Berenson J, Yelli O, Quiery A, Brady J, Patel R, **Wong SF**, Colbourn D, Gravenor D, Tiffany N, Shamasunder HK, and Wirtschafter E. "A Retrospective Study to Evaluate Bone Loss and Disease in Patients with Monoclonal Gammopathy of Undermined Significance". *Clinical Lymphoma, Myeloma & Leukemia* 2011 August; 11 (4):336-41.
 21. Hershman D, Unger, J, Crew K, Moinpour C, Minasian L, Hansen L, Lew D, O'kane P, Wade JL, **Wong, SF**, Hortobagyi G, Meysken F, Albain K. "SWOG S0715: Randomized Placebo-Controlled Trial of Acetyl-L-Carnitine for the Prevention of Taxane-induced Neuropathy During Adjuvant Breast Cancer Therapy". *Journal of Clinical Oncology* 2013 June 10;31 (20):2627-33.
 22. **Wong SF**, Green V, Bounthavong M, Margeilth D. "Retrospective Evaluation to Examine the Efficacy and Safety of Reduced Dose of Pegfilgrastim in Breast Cancer Patients receiving Cytotoxic Chemotherapy". *Clinical Breast Cancer*. (submitted)
 23. **Wong SF**, Bounthavong M, Nguyen C, Bechtoldt K, Hernandez, E.: "Implementation and Preliminary Outcomes of a Comprehensive Oral Chemotherapy Management Clinic". *American Journal of Health-System Pharmacists* 2014 June 1; 71(11): 960-5.
 24. **Wong SF**, Bounthavong M, Nguyen C, Chen T: "Outcome Assessments and Cost Avoidance of a Comprehensive Oral Chemotherapy Management Clinic". *Journal of National Comprehensive Cancer Network*. *Journal of National Comprehensive Cancer Network* 2016 March 14(4): 279-285.

Non-peer reviewed

1. **Wong, SF**. "Outpatient Administration of Paclitaxel". California Journal of Hospital Pharmacists 1994: Vol 6 (7); 11-14.
2. **Wong SF**. "Humanistic Approaches to the Management of Pain". Humanism 1998: Vol 3(1); 23-25.
3. Pon D and **Wong SF**. "Oral Targeted Agents". California Pharmacists Winter 2009; 44-49.

Chapters in Books

1. **Wong SF** & Westendorp J. Chapter 20: Investigational Agents and Procurement of Research Study Drugs. In: Klimaszewski AD, et al, eds. Manual for Clinical Trials Nursing. Oncology Nursing Press, Inc., 2000:93-98.
2. **Wong SF**. Chapter 40: Drug Accountability. In: Klimaszewski AD, et al, eds. Manual for Clinical Trials Nursing. Oncology Nursing Press, Inc., 2000:191-195.
3. **Wong SF** & Westendorp J. Chapter 25: Investigational Agents and Procurement of Research Study Drugs. In: Klimaszewski AD, et al, eds. Manual for Clinical Trials Nursing. Oncology Nursing Press, Inc., 2nd edition, 2008: 179-188
4. **Wong SF**. Chapter 49: Drug Accountability. In: Klimaszewski AD, et al, eds. Manual for Clinical Trials Nursing. Oncology Nursing Press, Inc., 2nd edition, 2008:339-344.
5. Chase DM, **Wong SF**, Wenzel L, & Monk B. Chapter 20:Palliative Care and Quality of Life. In ; DiSaia & Creasman, eds. Clinical Gynecologic Oncology, 8th edition. Philadelphia, PA. Elsevier-Saunders. 2012:597-630.
6. **Wong SF**, Bales, CA, & Hurtado, K. Chapter 27: Investigational Agents: Procurement, Accountability and Administration of Research Study Drug. Manual for Clinical Trials Nursing. Oncology Nursing Press, Inc., 3rd edition, 2016:259-270.
7. Chase DM, **Wong SF**, Wenzel L, & Monk B. Chapter 20:Palliative Care and Quality of Life. In ; DiSaia & Creasman, eds. Clinical Gynecologic Oncology, 9th edition. Philadelphia, PA. Elsevier-Saunders. (submitted)

Abstracts

1. Kuo S, Finck S, Cho J, Glenn D, **Wong SF** , Billups T, et al. "Continuous Ambulatory Infusional 5-Fluorouracil (5-FU) Chemotherapy in Advanced Colorectal Cancer: A Single Institutional Retrospective Study." (Abstract). Proceedings of the American Society of Clinical Oncology 1989:491
2. Le-Ta G, **Wong SF**, Kuo S, and Armentrout S. "Continuous Infusional 5-Fluorouracil (5-FU) in the Treatment of Advanced Colorectal Cancer" (Abstract). Proceedings of the American Society of Clinical Oncology 1991:Vol 10;251.
3. Cho J, Hurtado N, **Wong SF**, Armentrout S, Meyskens F, White C, et al. "Phase I-II Trial of Cyclosporin A (CSA), Cisplatin (CDDP), and VP-16 in Non-small cell Lung Cancer (NSCLC)" (Abstract). Proceedings of the American Society of Clinical Oncology 1991:Vol 10;152.
4. **Wong SF**, Ishida D, & Armentrout S. "Complications and Adverse Effects of Ambulatory Continuous Infusion Therapy" (Abstract). Proceedings of the American Society of Clinical Oncology 1992:Vol 11:397.
5. **Wong SF**, Schlutz M, & Armentrout S. "A Pilot Trial of Chronic Continuous Infusion of 5-Fluorouracil and Interferon in the Treatment of Gastrointestinal Malignancies" (Abstract). Proceedings of the American Society of Clinical Oncology 1993:Vol 12:221.

6. Atiba J, Jamil S, Meyskens FL, Cho J, Armentrout S, Berkson P, **Wong SF**, Neal J. "Trans-retinoic Acid (tRA) in the Treatment of Malignant Gliomas (MG)" (Abstract). Proceedings of the American Society of Clinical Oncology 1994:Vol 13:178.
7. Cho J, Ross H, Osann K, Downey-Hurtado N, **Wong SF**, Slater L. "Two Year Survival of Stage IV Non-Small Cell Lung Cancer (NSCLC) Patients Is Enhanced by Low Dose Cyclosporin A (CsA) Combined with Cis-Platinum (CDDP) and VP-16". (Abstract). Proceedings of the American Society of Clinical Oncology 1996:Vol 15:190.
8. **Wong SF**, Ho B, & Olegario R. "Evaluation of the cost-effectiveness of replacing IV ondansetron with oral granisetron in cisplatin- or carboplatin-based chemotherapy." (Abstract #301). Proceedings of the American Society of Clinical Oncology 1997:Vol 16:86a.
9. **Wong SF**, Kusanoo S, Keuroghelian K, Lim S, & Ho W. "Oral Granisetron as Prophylactic Antiemetic in Bone Marrow Transplantation Conditioning Regimens." (Abstract #279). Proceedings of the American Society of Clinical Oncology 1998:Vol 17:72a.
10. Wilder-Smith P, **Wong SF**, Ku N, & Kurosaki T. "Laser Effects on Oral Mucositis in Patients Receiving Chemotherapy". (Abstract). Proceedings of the American Society of Clinical Oncology, 1999:Vol 18;586a. (Poster Presentation)
11. **Wong SF**, Law A, Chau HV, Keuroghelian S, Lim S, & Ho W. "Pharmacoeconomic Analysis of IV Ondansetron vs Oral Granisetron in Conditioning Regimens" (Abstract) International Bone Marrow Transplant Registry/Autologous Blood and Marrow Transplant Registry Annual Meeting, March 2000, Anaheim, California. (Poster Presentation)
12. Chau HV, Lim D, Franson K, & **Wong SF** "Implementation of an Assessment Method for the Recognition of Depression in Cancer Patients" American College of Clinical Pharmacy 2002 Spring Practice and Research Forum, Savannah, Georgia. (Poster Presentation)
13. Chan Holly & **Wong SF** "Clinical and Economic Outcomes of A Formulary Change From Filgrastim (G-CSF) To Sargramostim (GM-CSF) in Patients Receiving Myelosuppressive Chemotherapy." American College of Clinical Pharmacy 2002 Fall Annual Meeting, Albuquerque, New Mexico (Poster Presentation)
14. **Wong SF**, Brown M, and Sarakain R "Retrospective Study of the Appropriate Utilization of Epoetin alfa and Darbepoetin alfa in Cancer Patients with Anemia." American College of Clinical Pharmacy 2004 Fall Annual Meeting, Dallas, Texas. . (Poster Presentation)
15. **Wong SF**. "Prospective Surveillance of Delayed Chemotherapy-induced Nausea and Vomiting (CINV) in a Private Practice Oncology Office". American Society of Health System Pharmacists Midyear Meeting, December 2004, Orlando, Florida. (Poster Presentation)
16. **Wong SF**, Ugai J, & Quist R. "A Pilot Study to Evaluate the Efficacy and Safety of Palonosetron (Aloxi™) in Combination with Multiple-Day Dosing of Corticosteroid for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in a Community Oncology Practice." Hematology Oncology Pharmacy Association Annual Meeting, June 2005, San Diego, California. (Poster Presentation)
17. **Wong SF**, Quist R, and Murray W. "Effectiveness of Examination Blueprints to Promote Higher Cognitive Level Performance." American Association of Colleges of Pharmacy 2006 Annual Meeting and Seminars, San Diego, California. (Poster Presentation)
18. Chen T, Matten P, Rutledge D, Quist R, Chung E, and **Wong SF**. "Implementing a Tobacco Cessation Training Program for Healthcare Professional in a Community Hospital Setting." American College of Clinical Pharmacy 2006 Fall Annual Meeting, St Louis, Missouri. Abstract 307E. (Encore Poster Presentation)
19. **Wong SF**. "Implementation of a Pharmacist-Directed Research and Clinical Program at a Medical Oncology Private Practice Office." American College of Clinical Pharmacy 2006 Fall Annual Meeting, St Louis, Missouri. Abstract 339. (Poster Presentation)
20. Chen T, Matten P, Rutledge D, Chung E, and **Wong SF**. "A Pilot Study to Assess the Long Term Effectiveness of a Community Based Smoking/Tobacco Cessation Training Program for Healthcare Practitioners: A 3-Month Interim Analysis." American College of Clinical Pharmacy 2006 Fall Annual Meeting, St Louis, Missouri. Abstract 83. (Platform Presentation)
21. Chen T, Matten P, Rutledge D, Chung E, and **Wong SF**. "A Pilot Study to Assess the Long Term Effectiveness of a Community Based Smoking/Tobacco Cessation Training Program for Healthcare Practitioners: A 3-Month Interim Analysis." American College of Clinical Pharmacy 2006 Fall Annual Meeting, St Louis, Missouri. Abstract 83. (Platform Presentation)

22. **Wong SF.** "Implementation of a Pharmacist-Directed Research and Clinical Program at a Medical Oncology Private Practice Office." American College of Clinical Pharmacy 2006 Fall Annual Meeting, St Louis, Missouri. Abstract 339. (Poster Presentation)
23. Rutledge D, Matten P, Chen T, Quist R, Chung E, and **Wong SF.** "Evaluation of a Hospital Staff Training Program Focused on Smoking Cessation for Patients" Oncology Nursing Forum 34 (1):168 (Poster Presentation)
24. **Wong SF,** Lloyd K, Chen T, Vasko C, Mummaneni M and Osann K. "A Pilot Cross-over Study to Evaluate the Use of Regenecare™ Topical Gel in Patients with Cutaneous Toxicity caused by Epidermal Growth Factor Receptor (HER1/EGFR) Inhibitors" Oncology Nursing Forum 34 (1):168 (Abstract 126) . (Poster Presentation)
25. Matten P, Fischel, R, Vu, D, & **Wong SF.** "Managing the Patient at Risk for Lung Cancer Through CT Lung Screening in a Community Hospital Setting" Oncology Nurse Society 32nd Congress Meeting, April 2007, Las Vegas, NV. (Platform Presentation) Matten P, Chung E, Rutledge D, & **Wong SF** "Implementing a Tobacco Cessation Training Program for Staff Nurses in a Community Hospital Setting" Oncology Nurse Society 32nd Congress Meeting, April 2007, Las Vegas, NV. (Platform Presentation)
26. **Wong SF,** Lloyd K, Vasko C, Mummaneni M and Osann K. "A Pilot Cross-over Study to Evaluate the Use of Regenecare™ Topical Gel in Patients with Cutaneous Toxicity caused by Epidermal Growth Factor Receptor (HER1/EGFR) Inhibitors- an Interim Analysis" American Society of Clinical Oncology (ASCO) Annual Meeting June 2007. (Online publication)
27. **Wong SF.** "Implementation of a Pharmacist-Directed Research and Clinical Program at a Medical Oncology Private Practice Office." Journal of Oncology Pharmacy Practice 2007; 13:173-176 (E25).
28. **Wong SF,** Lloyd K, Vasko C, Mummaneni M and Osann K. "A Pilot Cross-over Study to Evaluate the Use of Regenecare™ Topical Gel in Patients with Cutaneous Toxicity caused by Epidermal Growth Factor Receptor (HER1/EGFR) Inhibitors- an Interim Analysis" Journal of Oncology Pharmacy Practice 2007; 13:173-176 (E26).
29. Lin J, Quist R, Brown M, Sarakain R and **Wong SF.** "Retrospective evaluation of the appropriate utilization of darbepoetin alfa and epoetin alfa in cancer patients with anemia." ACCP Annual Meeting (October 14–17, 2007) in Denver, CO. (Poster Presentation)
30. Berenson JR, Yellin O, Boccia RV, Flam M, **Wong S-F,** Batuman O, Moezi MM, Woytowitz D, Duvivier H, Nassir Y and Swift RA "Zoledronic Acid Markedly Improves Bone Mineral Density for Patients with Monoclonal Gammopathy of Undetermined Significance and Bone Loss," Blood (ASH Annual Meeting Abstracts) 2007 110: Abstract 3606 (Poster Presentation)
31. Berenson JR, Yellin O, Boccia RV, Flam M, **Wong S-F,** Batuman O, Moezi MM, Woytowitz D, Duvivier H, Nassir Y and Swift RA "Zoledronic Acid Markedly Improves Bone Mineral Density for Patients with Monoclonal Gammopathy of Undetermined Significance and Bone Loss," J Clin Oncol 26: 2008 (May 20 suppl; abstr 8550) (Poster Presentation)
32. **Wong SF,** Osann K, Lloyd K, Lindgren A, Vasko K, Arenos R, Byun T, Mummaneni M. "Pilot cross-over study to evaluate Regenecare topical gel in patients with epidermal growth factor receptor (HER1/EGFR) inhibitors-induced skin toxicity. The Final Analysis. "American Society of Clinical Oncology (ASCO) Annual Meeting June 2008. J Clin Oncol 26: 2008 (May 20 suppl; abstr 20507)
33. **Wong SF,** Osann K, Lloyd K, Lindgren A, Vasko K, Arenos R, Byun T, Mummaneni M. "Pilot cross-over study to evaluate Regenecare topical gel in patients with epidermal growth factor receptor (HER1/EGFR) inhibitors-induced skin toxicity. The Final Analysis. " Journal of Oncology Pharmacy Practice (JOPP) 2008; 14(2):86 (EN1)
34. **Wong SF.** "A Cost benefit analysis of a novel oncology pharmacy practice model in a private medical oncology office". Journal of Oncology Pharmacy Practice (JOPP) 2008; 14(2):91. (PR8)
35. Nguyen H and **Wong SF.** "'Spontaneous Regression of Erlotinib-Induced Papulopustular Rash: Need for New Management Approach?" (Abstract 0006) Hematology Oncology Pharmacy Association HOPA 2010 Annual Meeting (Poster Presentation)
36. Liang C and **Wong SF.** "Utilization of Evidence-Based Assessment to Develop Warfarin Protocol for Management of Venous Thromboembolism in Oncology Patients at an Oncology Medical Office". (Abstract 0010) Hematology Oncology Pharmacy Association HOPA 2010 Annual Meeting (Poster Presentation)
37. Yang S, Vuong G, Bach T, & **Wong SF.** "Cost-Benefit Analysis of a Darbepoetin alfa Administration Order Form at a Private Oncology Practice" (Abstract 0011) Hematology Oncology Pharmacy Association HOPA 2010 Annual Meeting (Poster Presentation)

38. **Wong SF**, Nguyen HP, Green V, Byun TE, Grahn EP, Lindgren T. "Erlotinib-induced papulopustular rash: Need for new management approach". J Clin Oncol 28, 2010 (suppl; abstr e13647)
39. Nguyen M, **Wong SF**, Chung E, Pham DQ, Law A. "Evaluating the Effectiveness of a Question-Based Learning Method to Promote a Student-centered Learning Paradigm". American Association of Colleges of Pharmacy 2010 Annual Meeting.
40. Pham DQ, **Wong SF**, Vats V, Campbell A, Chung EP, Schwartzman E, Hata M. "Outcome evaluation of a newly implemented Interprofessional Education (IPE) course using a College of Pharmacy Objective Structured Clinical Examination (OSCE) as an assessment tool". American Association of Colleges of Pharmacy 2010 Annual Meeting.
41. Green V, Bounthavong M, Marglieth D, **Wong SF**. "Retrospective Evaluation to Examine Efficacy and Safety of Half-dose Pegfilgrastim in Breast Cancer Patients Receiving Cytotoxic Chemotherapy". (Abstract #116) 2010 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium.
42. Hershman D, Unger, J, Crew K, Moinpour C, Minasian L, Hansen L, Lew D, Okane P, Wade JL, **Wong SF**, Hortobagyi G, Meysken F, Albain K. "SWOG S0715: Randomized Placebo-Controlled Trial of Acetyl-L-Carnitine for the Prevention of Taxane-induced Neuropathy During Adjuvant Breast Cancer Therapy" 2012 American Society of Clinical Oncology (ASCO) Annual Meeting, J Clin Oncol 30, 2012 (suppl; abstr 9018)
43. Mirshahidi H, Hernandez, E, Ta M, Baylon S, Pham M, Lee B, Jahng P, Kung L, **Wong SF**. "Comparative Effectiveness Assessment of a Lung Cancer Multidisciplinary Practice to Improve Patient Care" 2012 American Society of Clinical Oncology (ASCO) Annual Meeting. J Clin Oncol 30, 2012 (suppl, abstr e16523).
44. Khan S, Yuan Y, Valenzuela M, Turay D, Ferguson H, **Wong SF**, Perez M, Mirshahidi S, Wall N. "Early diagnostic value of survivin and its alternative splice variants in breast cancers" 2012 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium. (Abstract ID 103186)
45. **Wong SF**, Bounthavong M, Nguyen C, Chen T. "Outcome Assessments and Cost Avoidance of a Comprehensive Oral Chemotherapy Management Clinic" 2015 Hematology Oncology Pharmacy Association (HOPA) Annual Meeting. Journal of Oncology Pharmacy Practice Volume 21 Number 2 (Supplement) April 2015. (Poster Presentation – Abstract# PM14)

Rev:11/2015